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ABSTRACT 
Objective: Self-report of medication adherence is commonly used in research studies, 
but the information is lacking about the sensitivity, specificity, reliability and clinical 
validity of this method. The purpose of this study was to test the sensitivity, specificity 
and reliability of several methods for accessing medication compliance using patient 
self-report of adherence. The Medication Event Monitoring System (MEMS) was used 
as a standard against which self-report measures were compared. 
Design: Cross sectional study. 
Data Collection: A self-reported questionnaire accessed compliance of Anti-retroviral 
therapy (ART) and Protease inhibitors (PI) used by the patients with IIlV infection 
during the year 1996-1997. The eligibility criteria included ages between 18-74 years, 
a current prescription of ART or PL One hundred and forty- five patients completed 
the questionnaire out of which a subset of 86 patients were randomly selected to 
receive a 30-day supply of their prescribed anti-retroviral in a vial with MEMS Track 
cap. After a period of one month the data was retrieved using MEMS-4 communicator. 
Data on demographics, mood status, medical status and clinical characteristics was 
also obtained by survey. 
Methodology: Sensitivity, specificity and reliability were calculated for the following 
self-report measures: number of doses missed in past one month, number of doses 
missed in past three months, Medication Adherence Scale (MAS) and temptation to 
skip medication scale. The patient population was divided into two groups, i.e., the 
patients on PI and patients on ART. MEMS report was used as a standard for 
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comparison of the self-reported compliance. Two different gold standards were set. 
>80% compliance MEMS and >90% compliance MEMS to test the compliance at 
80% and 90% cutoffs. 
Results: For patients on Protease inhibitors, the agreement between Self-report and 
MEMS-report according to kappa statistics was K= 0.14 (for >80% compliance 
MEMS) and K=0.11 (for >90% compliance MEMS) indicating only slight agreement 
between the two measures of compliance. Number of doses missed in past one month 
and number of doses missed in the past three months had the highest sensitivity of 
1.00, but the specificity of these measures was very poor. MAS had the highest values 
of kappa (K=0.26) indicating a fair amount of agreement with MEMS. Temptation to 
skip medication scale showed a good balance of sensitivity and specificity, indicating 
good accuracy. For patients on ART the agreement between the Self-report and 
MEMS-report according to the kappa statistics was K=0.15 (for >80% compliance 
MEMS) and K=0.20 (for >90% compliance MEMS) indicating only slight agreement 
between the two measures of compliance. In congruence with the results for PI 
patients, number of dose missed in past one month and number of doses missed in past 
three months overestimated adherence. MAS had the highest kappa value of K=0.33 
indicating fair agreement with MEMS and temptation to skip medication showed a 
good balance between sensitivity and specificity, similar to PI patients. 
Conclusion: Sensitivity and specificity are the measures of accuracy of the data. 
Number of doses missed in past one month and number of doses missed in the past 
three months showed highest sensitivity, indicating that this measure correctly 
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classified the complaint patients in the complaint category. At the same time these 
measures had a very low specificity indicating that the non-compliant patients were 
also incorrectly classified as compliant, causing overestimation of compliance 
behavior, leading to erroneous results. MAS and temptation to skip medication 
measures also overestimated adherence, concluding a very low accuracy of these 
measures in detecting compliance. Kappa statistics is an index of reliability. All the 
self-report measures only showed a slight to fair agreement with MEMS reported 
compliance indicating a very low reliability of these self-report measures in measuring 
compliance. Additional studies will be required to determine if these findings also 
apply to other populations. 
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INTRODUCTION 
Adherence, often used interchangeably with compliance, is "the act, action, or quality 
of being consistent" [1] with administration of prescribed medications. Adherence is 
preferred because it affirms that a patient actively participates in choosing and 
maintaining a medication regimen. Nonadherence may mean not talcing medication at 
all, taking reduced amounts, not talcing doses at prescribed frequencies or intervals or 
not matching medication to food requirements [2]. Typical rates of medication 
adherence for persons with chronic disease are about 50%, with a range from 0% to 
100% [3]. 
A] Importance of Adherence 
As protease inhibitors and triple drug combinations have become the standard of care 
for most HIV patients, adherence to HIV medication regimens has become an 
important issue [4] . Since HIV has the ability to mutate rapidly in absence of drug or 
at sub- therapeutic doses, taking anti-retroviral medication exactly as prescribed is the 
required the success of antiretroviral therapy [5,2]. 
Adherence to anti-retroviral therapy for the treatment of HIV infection and AIDS has 
become one of the most important clinical challenges among HIV health care 
providers and patients [4,6]. One hundred percent adherence to current anti-retroviral 
regimen however is not easy to achieve. Research on adherence of HIV therapy ranges 
from 46% to 88% [7-10] . It has also been shown that adherence normally decreases 
over time and with greater number of pills that one is required to take. 
1 
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Improvement of adherence is key to preventing the emergence of drug-resistant 
viruses that compromise therapeutic benefits and may be transmitted to others. 
Furthermore, the cost of interventions to enhance adherence is minimal as compared to 
the cost of the therapy [2]. 
B] Measuring Adherence: 
The measurement of adherence poses a challenge to researchers and clinicians. There 
are a number of ways to measure adherence or compliance [ 11, 16]. 
Current detection methods include indirect measures, such as self-report, interviews, 
therapeutic outcomes, pill count, change in the weight of meter-dose inhaler canisters, 
medication refill rate and computerized compliance monitors, and direct measures, 
such as biologic markers, tracer compounds, and biologic assay of body fluids [12]. 
Plasma and urinary drug levels provide useful objective assessment of adherence but 
are often subject to wide individual variation in drug pharmacokinetics [13]. Drug 
levels may only reflect doses taken the previous day rather than adherence over the 
previous week or month [14]. This problem is particularly true for medications with 
short half-lives. In addition, most drug assays are expensive and subject to multiple 
confounding sample methods [14,15]. 
Pill count is another common detection method used to measure compliance. It is 
frequently used in clinical drug studies, but the results can be confounded if unused 
bottles are misplaced or deliberately not returned to the providers also called "pill-
2 
dumping" [16]. In addition, pill counts do not reveal whether a medication is taken 
consistently or at correct dosing intervals. 
Refill records at pharmacies capture the quantity of medication presumably consumed 
between visits but cannot verify correct timing of doses or the actual taking of 
medication [17]. 
Self-report and interviews with patients are the most common and simplest methods 
of attempting to determine compliance with the therapy [12]. It is the only method 
that can detect the underlying issues related to non-adherence behavior, and it is 
therefore critical to incorporate some type of self-report in evaluating an adherence 
strategy [18]. 
This method has an advantage of low cost, results are easily obtainable and the 
method can be tailored to the language and reading competency of the subjects. 
Disadvantages of this method include: overestimation of adherence, recall bias and 
the fact that this method often gives information only on short-term adherence or 
average adherence. One of the ways suggested to improve self-reporting methods is 
to include computer-assisted interviews, which may give more accurate results 
especially on sensitive questions [19]. 
The method in which 'self-report' is administered is an important aspect of getting 
useful information from patients. The way in which the questions are asked also 
plays a role in the quality of information received. Phrasing the question in a non-
judgmental way and asking for specific information has been found to be critical in 
obtaining important information on how the patient is managing with adherence. 
3 
Some examples of this are: "It is sometimes difficult to take these medications 
exactly on time. How many doses have you missed in the past 24 hours?" and "Do 
you miss some of your medications each week?" [18). 
One study found that phrasing question to elicit a "yes" response to non-adherence 
behavior allowed patient to disclose actual behavior more readily because the patients 
have the tendency to answer providers in the affirmative [20). This supports the 
notion that providers will get more accurate information if they give their patients 
permission to be honest about their difficultly in taking medication. 
An ideal method for measuring compliance should measure compliance at the time 
and place of medication-taking event. It should, therefore, possess perfect sensitivity 
and specificity. Although direct observation of the patient would come closest to 
satisfying the definition, this method is not practical. 
Computerized compliance monitors are the most recent and reliable source of indirect 
detection methods. Hence they were used in this study as a gold standard to compare 
self-report measures. The principle of electronic monitoring of compliance was 
pioneered by Kass et al., [21,22] with the development of an electronic eye-drop 
dispenser. Electronic monitoring also has been used to measure compliance with 
solid dosage forms (Medication Event Monitoring Systems [MEMS] available from 
Aprex Corporation, Fremont, Califomia.)[21,22). This technique uses a computer 
chip in the cap to record the time when the medication bottle is opened and 
presumably a pill is taken. This method has the disadvantages of underestimating the 
adherence if multiple doses are removed at one time or estimating adherence if the 
4 
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medication is not actually taken, it is expensive and it also requires specific software 
for interpretation. 
C] Measurement Error 
A certain amount of error is intrinsic to any measurement process. In the conduct of 
epidemiologic research, measurement error is potentially a major problem that may 
invalidate the results of otherwise well-designed studies. Although measurement error 
can never be eliminated, the methods for minimizing the impact can contribute greatly 
to the quality of epidemiologic studies and to the appropriateness of the conclusions 
drawn from them. 
Indices of accuracy of measurement: 
The accuracy, or validity, of a measurement refers to the extent to which the 
measurement represents the true value of the attribute being assessed. In order to 
obtain something more than an impressionistic idea of the quality of a measurement of 
a given variable, it is useful to calculate quantitative indices of the accuracy of 
measurement. For a discrete variable there are two separate aspects of the accuracy of 
measurement. One is sensitivity, which is defined as the proportion of those who truly 
have the characteristic that are correctly classified as having it by the measurement 
technique [23]. The other is specificity, which is defined as the proportion of those 
who truly do not have the characteristic that are correctly classified as not having it by 
the measurement technique [23]. Measurement of a binary characteristic is perfect 
when both sensitivity and specificity are 100%. When sensitivity is equal to 100% 
5 
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minus specificity, then the measurement technique is no better than an entirely random 
mean of classifying individuals, which indicated that the probability of being 
identified as having characteristic is same for those who do not have the characteristic. 
In order for a measurement technique to be useful in epiderniologic research, it must 
be substantially better than a random method of classification. 
Indices of reliability: 
In many epidemiologic studies, it is important to assess the degree of correspondence 
of two qualitatively differently methods of measurement, such as information on use 
of medications obtained through interviews compared with similar information 
obtained through review records. The extent of their agreement in classifying the 
individuals would then reflect the reliability of the measure used. 
The kappa coefficient is appropriate for comparing agreement between discrete 
variables. The kappa coefficient, which was first proposed by Cohen (1960), has the 
important characteristic of correcting for the chance agreement that would be expected 
to occur if the two classifications were completely unrelated. Failure to take into 
account chance agreement can lead to erroneous conclusions about the quality of 
measurement. 
The relationship of kappa to sensitivity and specificity under the assumption of 
independent error is more complex and is a function not only of these two indices of 
accuracy, but also of the true proportion of the population that in fact has the 
characteristic of interest (compliant) [24,25]. Consequently, even for fixed values of 
6 
sensitivity and specificity, the value of kappa can vary widely, so that inferences about 
accuracy based on the value of kappa are difficult to draw. 
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METHODOLOGY 
Study Sample 
The sample consisted of 145 patients who were currently prescribed medication for 
IDV. Eligibility criteria included age between 18 and 74 years, a current prescription 
of approved anti-retroviral medication or protease inhibitors or use of approved 
medication for IDV-related complications and prophylaxis of opportunistic infections 
(for example, trimethoprim, sulfamethoxazole used in the prophylaxis of 
Pneumocystic carinii pneumonia), ability to read English, and positive IDV status. The 
purpose of the original study for which the data was gathered was to develop measures 
of stages of change for medication adherence. The study was funded by NIH and 
conducted by Dr. Cynthia Willey, at the University of Rhode Island during the year 
1995-1998. 
The study sites are described below: 
1. The Miriam Hospital Immunology Center, which has the largest number of 
ambulatory visits of IDV seropositive individuals and serves the majority of 
HIV+ women in Rhode Island. 
2. Stanley Street Treatment and Resources, which provides primary care for the 
indigent and intravenous drug using population in the greater Fall River 
Massachusetts area. 
3. Veterans Affairs Medical Center in Providence RI, which currently provides 
care to approximately 60 IDV seropositive men. 
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Data Collection 
Patients meeting the above criteria who visited one of the three sites were asked to fill 
out a standardized questionnaire. The patients were told that the questionnaire was 
about how they think and feel about the HIV related medications that they were 
taking, and about different strategies that people use to take their medications. They 
had the choice to complete it at home and mail it in return to the clinic, or complete it 
right at the clinic. They were told they would receive a gift certificate of $20 after 
they had turned in the questionnaire. The data was collected during the year 1996-
1997. After completion of the questionnaire, a subset of patients (n=86) were 
randomly selected to receive a 30-day supply of their prescribed medication in a vial 
with Medication Event Monitoring System (MEMS) TrackCap™ (APREX 
Corporation, Union City, California). A second appointment was scheduled for 1 
month later, and data from the MEMS TrackCap were read using a MEMS-4 
Communicator. All patients were offered a $50 gift certificate for their participation 
in the MEMS portion of the study. 
The survey questionnaire administered to patients included data on demographics, 
living arrangements, education, employment, income, insurance, social support, side 
effects and a psychological measurement scale. It was a self-reported questionnaire. 
The answers were checked for completeness. 
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Measures and Variables Assessed 
The questionnaire included the following questions: 
• Demographics: age, gender, race, years of education, income, insurance, 
number in household, current health status and employment. 
• Mood status. 
• Economic status: cost of regimen, insurance coverage. 
• Physical functioning: weeks in bed, hospitalization. 
• Medical status: self reported disease and medication history, # of doses 
missed. 
• Coping: coping with normal work outside and at home. 
• Social support: support from family and friends and other health care 
providers. 
• Side effects. 
Sensitivity and Specificity were calculated for the following self-report measures. 
1. Number of dosed missed in past one month. 
2. Number of doses missed in past three months. 
3. Medication adherence scale. 
4. Temptation to skip medication scale. 
I. Number of doses missed in past one month: This was a self-reported answer to the 
question "how many doses of medication have you missed in the past one month". 
Higher numbers indicate worse compliance. 
9 
2. Number of doses missed in past three months: This was a self-reported answer to 
the question "how many doses of medication have you missed in the past three 
months". 
Higher numbers indicate worse compliance. 
3. Medication Adherence Scale: MAS or Medication Adherence Scale is a previously 
validated scale to measure compliance [26]. It contains six questions that are answered 
"yes" or "no". Each patient scored two for every 'yes' and one for every 'no'. A 
positive response indicates a problem with adherence and the total score range from 6-
12, with higher scores indicating poorer adherence. The following questions are 
included in this scale: 
• During the last 3 months, have you ever stopped taking your protease 
inhibitor/ antiretroviral medication because you felt better? 
• During the last 3 months, have you ever stopped taking your protease 
inhibitor/ antiretroviral medication because you felt worse? 
• During the last 3 months, have you ever forgotten to take your protease 
inhibitor/ antiretroviral medication? 
• During the last 3 months, have you at times been careless about taking your 
protease inhibitor/ antiretroviral medication? 
• During the last 3 months, have you ever taken less of your protease inhibitor/ 
antiretroviral medicine than your doctor prescribed because you felt better? 
• During the last 3 months, have you ever taken less of your protease inhibitor/ 
antiretroviral medicine than your doctor prescribed because you felt worse? 
10 
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4. Temptation to skip medication scale: This scale was developed to measure self-
reported likelihood of non-compliance (Willey, C et al., manuscript in progress). The 
items on the temptation scale were based upon predictors of compliance from the 
literature and included situations that might affect the taking of protease inhibitors or 
anti-retrovirals as directed. Responses for each situation rated how tempted the patient 
would be to skip their protease inhibitor medication. The responses were measured on 
a five-point Likert scale (continuous) with l=not tempted to 5=extremely tempted. 
A few of the items on temptation to skip medication scale include: 
• When you feel good and think you don't need it. 
• When you are anxious about the side effects. 
• When you want to save on the cost of medication. 
• When your doctor doesn' t seem interested in whether you take your 
medication. 
• When you start feeling better. 
3 categories were developed: 
a. Temptation to skip medication due to side effects 
• When you are anxious about side effects. 
• When you experience minor side effects. 
• When you feel you should give your body a rest. 
• When you worry that the chemicals in the medication might harm your body. 
11 
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b. Temptation to skip medication due to lack of support 
• When your family and friends don't seem concerned enough about your 
condition. 
• When your doctor doesn't seem concerned enough about your condition. 
• When your insurance doesn ' t cover the cost of your medication. 
• When you lose confidence in your doctor. 
c. Temptation to skip medication when feeling good 
• When you feel good and think you don't need it. 
• When your medical condition doesn't seem that bad. 
• When it seems too complex to keep track of all your medications. 
• When you aren ' t sure if the medication is really helping you. 
d. Total Scale 
Scores on each sub-categories were obtained by adding items under each subscale. 
Score on total scale was obtained by summing all the items under all the sub-
categories. 
Variables Used: 
The variables were coded as follows : 
Demographic characteristics 
Age: Categorical (AGEGRP) 
~ 25yrs: 1 
26-35yrs: 2 
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36-45yrs: 3 
46-55yrs: 4 
Sex: Categorical 
Male: M 
Female: F 
Race: Categorical 
White, non-Hispanics: 1 
Hispanics: 2 
African American: 3 
Native American: 4 
Asian: 5 
Others: 6 
Years of education: Categorical (EDU) 
>12yrs: 1 
12yrs: 2 
13-15yrs: 3 
16+yrs: 4 
Annual Income: Categorical 
Less than $15,000: 1 
$15,000 to $24,000: 2 
$25,000 to $34,000: 3 
$35,000 to $44,000: 4 
13 
$45,000 to more: 5 
Current health status: Categorical 
Excellent: 1 
Very good: 2 
Good: 3 
Fair: 4 
Poor: 5 
Insurance: Categorical 
No insurance: 1 
Insurance: 2 
Employment status: Categorical (EMP) 
Employed: 1 
Not employed: 2 
T-Cell count last tested: Categorical 
>500: 1 
201-500: 2 
50-200: 3 
Less than 50: 4 
There were three different classes of drugs prescribed to the patients, DRUG 1, 
DRUG 2 and DRUG 3. DRUG 1 mostly comprised of protease inhibitors and 
DRUG 2 mostly comprised of ART and DRUG 3 comprised of anti-infectives. 
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Total Population on Protease Inhibitors (Pl): All the patients who were 
prescribed protease inhibitor in DRUG 1 (thrice day) class comprised the total 
patient population on protease inhibitor. This set of patients was used for further 
analysis of patient population PI (n=82). 
Total Population on Anti-retrovirals (ART): All the patients who were prescribed 
anti-retrovirals in DRUG 2 class comprised the total patient population on ART. 
This set of patients was used for further analysis of patient population ART 
(n=66). All the drugs in DRUG 2 class had different dosing schedule ranging from 
2 times a day to 5 times a day, so the measures number of doses missed in past one 
month and number of doses missed in past three months were difficult to calculate 
for patient population on ART and so were not used for them. 
Statistical Analysis: 
Descriptive statistics were calculated for all self-report measures of compliance 
and for i\IBMS data. The data was analyzed using the Statistical Analysis System 
(SAS) Version 8.0 on IBM compatible computer at the University of Rhode 
Island. 
Compliance coding strategies 
A) Coding of self-report measures: 
For all the measures 0 =Compliant and 1= Non-compliant. 
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1. Number of dosed missed in the past one month: 
This was converted to % of doses missed in the past one month (OM) using the 
following formula: 
OM= [(90 - #of dosed missed in the past one month) I 90] * 100 
This measure was divided into two sub measures to test compliance at two 
different cutoffs ~ 80% compliance and ~ 90% compliance. 
OMI: ~ 80% Compliance 
OM2: ~ 90% Compliance 
OMJ: Categorical 
~ 80%: 0 
<80%: 1 
OM2: Categorical 
~ 90%: 0 
<90%: 1 
2. Number of doses missed in the past three months: This was converted to % 
of doses missed in the past three months (TM) using the following formula: 
TM= [(270 - #of dosed missed in the past three months) I 270] * 100 
This measure was divided into two sub measures to test compliance at two 
different cutoffs ~ 80% compliance and ~ 90% compliance. 
TMI: ~ 80% Compliance 
TM2: ~ 90% Compliance 
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TMJ: Categorical 
~ 80%: 0 
<80%: 1 
TM2: Categorical 
~ 90%: 0 
<90%: 1 
3. Medication Adherence Scale (MAS): This scale consisted of six questions to be 
answered yes/no. Where the patient scored 1- for every yes and 2- for every no. With 
the total score ranging from 6 to 12. 
This scale was recoded as 1 for every 'yes' and 0 for every 'no' to get the range from 
0-6. 
Total Score = Sum of the scores for all 6 answers. 
For patient population Protease inhibitors: The measure MAS was further divided 
in three sub-measures (PIMl, PIM2 and PIM3) to help determine the optimal scoring 
procedure for this self-report measure. 
PIMJ: Categorical 
MAS Scores: 0= 0 
MAS Scores: 1-6= 1 
PIM2: Categorical 
MAS Scores: 0 and 1= 0 
MAS Scores: 2-6=1 
PIM3: Categorical 
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MAS Scores: 0, 1and2 =0 
MAS Scores: 3-6 = 1 
For patient population on Antiretrovirals: The measure MAS was further divided in 
three sub-measures (AVMl, AVM2 and AVM3) to determined the optimal scoring 
procedure for this self-report measure. 
A VMJ: Categorical 
MAS Scores: 0= 0 
MAS Scores: 1-6= 1 
A VM2: Categorical 
MAS Scores: 0 and 1= 0 
MAS Scores: 2-6 = 1 
A VM3: Categorical 
MAS Scores: 0, 1 and 2=0 
MAS Scores: 3-6 = 1 
4. Temptation to skip medication scale: The responses for this scale were measured 
on a five point Likert scale (continuous) with 1= not tempted to 5= extremely 
tempted. 
This scale was further divided into two sub-scales: 
a. Temptation to skip medication 12 scale (TEMP 12): This scale included the twelve 
questions listed on pages 11-12. The total score ranged from 12 to 60 (each question 
contributing 1-5 points) with higher score indicating worse compliance. 
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b. Temptation to skip medication 13 scale (TEMP 13): This scale included the twelve 
questions listed in the above section with the addition of the question "When you feel 
like giving up". The purpose of including this particular question was to test the 
importance of this variable in measuring compliance. 
The total score ranged from 13 to 65 with higher score indicating worse compliance 
with each question contributing 1-5 points. 
For patient population Pl: TEMP 12 and TEMP 13 scales were coded as follows on 
the bases of the scores obtained. The cutoffs were determined on the basis of 
adequate distribution of patients in each category. 
Pl12Tl: Categorical 
Temp 12 Score: 12 = 0 
Temp 12 Score: 13-60 = 1 
P113Tl: Categorical 
Temp 13 Score: 13 = 0 
Temp 13 Score: 14-65 = 1 
For patient population ART: TEMP 12 and TEMP 13 scales were coded as follows 
on the bases of the scores obtained. The cutoffs were determined on the basis of 
adequate distribution of patients in each category. 
A V12Tl: Categorical 
Temp 12 Score: 12 = 0 
Temp 12 Score: 13-60 = 1 
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A V12T2: Categorical 
Temp 12 Score: 12 and 13 = 0 
Temp 12 Score: 14-60 = 1 
A V12T3: Categorical 
Temp 12 Score: 12, 13 and 14 = 0 
Temp 12 Score: 15-60 = 1 
A Vl3Tl: Categorical 
Temp Score: 12 = 0 
Temp Score: 13-65 = 1 
A Vl3T2: Categorical 
Temp 13 Score: 12 and 13 = 0 
Temp 13 Score: 14-65 = 1 
AV13T3: Categorical 
Temp 13 Score: 12, 13 and 14 = 0 
Temp 13 Score: 15-65 = 1 
B) Coding of MEMS measures: 
For all the MEMS measures 0 indicates compliant and 1 indicates non-compliant. 
Two MEMS measures were used as different gold standards. One indicating ~ 80% 
doses taken as prescribed, the other indicating~ 90% of doses taken as prescribed. 
MEMSl (Gold standard I): Tested the compliance at 80% cutoff. This measure was 
coded as follows: 
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MEMSl: Categorical 
~ 80%= 0 
<80%= 1 
MEMS2 (Gold standard II): Tested the compliance at 90% cutoff. This measure was 
coded as follows: 
MEMS2: Categorical 
~ 90%= 0 
<90%= 1 
Comparison of self-report measures with MEMS: 
For each patient a comparison of compliance behavior was made between self-report 
measures and MEMS reported compliance. True positive (A) indicated both the self-
report and the MEMS gold standard show compliance. False positive (B) indicated 
the self-report indicates compliance but the MEMS gold standard indicates 
noncompliance. False negative (C) indicated that the self-report indicates 
noncompliance but MEMS gold standard indicates compliance. True negative (D) 
indicated that both the self-report and MEMS gold standard both indicate 
noncompliance. 
Example considering Gold standard I (MEMS ~ 80% doses taken) and Self-report 
measure # 1 (% of doses taken in the past one month): 
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MEMS 
~80% <80% 
Compliant Compliant 
SELF-REPORT 
~ 80% of doses taken in 
the past one month 
< 80% of doses taken in 
the past one month 
A B 
c D 
Where A= True positive, B= False positive, C= False negative and D= True negative. 
Sensitivity and Specificity were calculated for all the measures. Sensitivity is defined 
as the proportion of the population who truly has the characteristics that are correctly 
classified as having it. 
Sensitivity= (true-positive) = 
(true positive+ false-negative) 
A 
(A+c) 
Specificity is defined as the proportion of the population who truly do not have the 
characteristic that are correctly classified as not having it. 
Sensitivity= (true-negative) = 
(true negative+ false-positive) 
D 
(B+D) 
Sensitivity and Specificity are the quantitative indices of the accuracy of measurement 
[27]. 
The overall agreement between the self-report and MEMS was measured using kappa 
statistics. Kappa statistics an index of reliability. Reliability, or reproducibility, refers 
to the extent to which results of a measurement can be replicated [2 7 ,23]. 
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Kappa coefficient (K) = Observed agreement - Expected agreement 
1- Expected agreement 
The kappa coefficient is an important characteristic of correcting for the chance 
agreement that would be expected to occur if two classifications were completely 
unrelated. Failure to take into account chance agreement can lead erroneous 
conclusions about the quality of measurement. Kappa performance was analyzed using 
standard nomenclature <0 poor; 0 to 0.2 slight; 0.21 to 0.4 fair; 0.41 to 0.6 moderate; 
0.61 to 0.8 substantial; 0.8 to 1 almost perfect [27 ,23]. 
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RESULTS 
A total population of 145 patients was enrolled in the original study. A sub-population 
of 86 patients participated in the MEMS monitoring. Demographic data is shown in 
table A. Eighty two of these were on protease inhibitors (Pl), and 66 patients were on 
anti-retroviral therapy (ART). The median age was 38.5 years and age ranged from 
26-55 years. White-non-Hispanics represented 80% of the 86 patient population, 
Hispanics 3.5%, African American 3.5% and Native Americans 6%. Most of the 
patients were uninsured (95%) and 58% were unemployed. Eighty six percent had at 
least high school education. More than half of the study population had an annual 
income of less than $15,000. Thirty-five percent had very good health status and 43% 
had good health status. 
I. For Population on Protease Inhibitor: 
A) Comparison between MEMS and % of doses missed in the past one month. 
For this measure n=68. This measure was compared with two different compliance 
levels i.e. • 80% compliance and • 90% compliance as determined by MEMS. 
Table 1-2 and Tables 12-13: Shows the agreement between compliance as measured 
by MEMS and by self-report % doses missed in the past one month. All the patients 
(68/68) were classified as compliant for~ 80% compliance# of doses missed in the 
past one month. In contrast, only (47/68) 69% were classified as ~ 80% compliance 
level by MEMS. This shows a clear indication of overestimation of adherence by self-
report. 
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The highest sensitivity i.e.100% was recorded for both ;;::: 80% compliance number of 
doses missed in the past one month and ;;::: 90% compliance of doses missed in the past 
one month, at both 80% and 90% cutoffs for MEMS. The specificity remained low, at 
all the above levels indicating a low accuracy of the measure. The value of kappa was 
0.00 and 0.13 for >80% number of doses missed in the past one month and >90% 
number of doses missed in the past one month respectively at >80% compliance 
determined by MEMS and 0.00 and 0.06 for >80% # of doses missed and >90% 
number of doses missed respectively at >90% compliance determined by MEMS 
indicating low reliability of the measure. 
B) Comparison between MEMS and % of doses missed in the past three months. 
For this measure n=68. The measure was studied at 2 different compliance levels i.e. 
>80% compliance and >90% compliance. 
Table 3-4 and Tables 14-15: Shows the agreement between MEMS and % doses 
missed in the past three months. 99% of the population was classified as compliant at 
>90% number of doses missed in the past three months, in contrast to 69% by MEMS 
report. 
The highest sensitivity i.e.100% was recorded for both >80% compliance number of 
doses missed in the past three months and >90% compliance number of doses missed 
in the past three months, at both 80% and 90% cutoffs for MEMS. The specificity 
remained low, at all the above levels indicating a low accuracy. The value of kappa 
was 0.00 and 0.05 for >80% number of doses missed in the past three months and 
>90% number of doses missed in the past three months respectively at >80% 
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compliance determined by MEMS and 0.00 and 0.03 for >80% number of doses 
missed in the past three months and >90% number of doses missed in the past three 
months respectively at >90% compliance determined by MEMS indicating low 
reliability of the measure. 
C) Comparison between MEMS and Medication Adherence Scale (MAS). 
For this measure the total population was n=67. Three different cutoff scores were 
used to determine which was the most useful. 
Table 5-7 and Tables 14-16: Shows the agreement between MEMS and Medication 
Adherence Scale. The highest sensitivity was seen when the score of 0,1 and 2 on 
MAS was set as compliant and the score 3 or more as noncompliant for both >80% 
and >90% of doses taken as measured by MEMS. The highest specificity was 
observed when the score of 0 was set as compliant and the score of lor more as non-
complaint at both 80% and 90% cutoff values for MEMS. The agreement with 
MEMS data was highest when scores of 0, 1 and 2 was set as compliant and 3 or more 
as non-complaint (K=0.37) for >80% compliance MEMS and when the score of 0 
was set as complaint and 1 or more as non-compliant (K=0.31) for >90% compliance 
MEMS indicating fair reliability. 
D) Comparison between MEMS and Temptation to skip medication scale 12 
(TEMP12). 
For this measure the total population was n=64. 
Table 8 and 17: Shows the agreement between MEMS and Temptation to skip 
medication scale 12. The total score on the scale ranged from 12-60. Two different 
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cutoff scores were used to determine the most useful level. When the cutoff score of 
12 was set as complaint and 13 and more as non-compliant, the sensitivity remained 
i.e. 0.52 for both >80% compliance and >90% compliance MEMS, but the specificity 
was higher at the >80% cutoff for MEMS (0.61) as compared to >90% cutoff for 
MEMS (0.55). This measure showed a low reliability at kappa values of 0.06 (>80% 
compliance MEMS) and 0.11 (>90% compliance MEMS). 
E) Comparison between MEMS and Temptation to skip medication scale 13 
(TEMP13). 
For this measure the total population was n=64. 
Table 9 and 18: Shows the agreement between MEMS and Temptation to skip 
medication scale 13. The total score on the scale ranged from 13-65. Two different 
cutoff scores were used to determine the most useful level. When the cutoff score of 
13 was set as complaint and 14 and more as non-compliant, the sensitivity remained 
the same i.e. 0.52 for both >80% compliance and >90% compliance MEMS, but the 
specificity was higher at the >80% cutoff for MEMS (0.61) as compared to >90% 
cutoff for MEMS (0.55). This measure showed a low reliability at kappa values of 
0.06 (>80% compliance MEMS) and 0.11 (>90% compliance MEMS). 
For patients on Anti-retroviral therapy: 
F) Comparison between MEMS and Medication Adherence Scale 
(MAS). 
For this measure the total population was n=62. Three different cutoff scores were 
used to determine which one was the most useful. 
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Table 19-21 and Tables 27-29: Shows the agreement between MEMS and 
Medication Adherence Scale. The total score on the scale ranged from 6-36. The 
highest sensitivity of 0.98 was seen when the score of 0, 1 and 2 was set as 
compliant and the score of 3 and more as non-compliant for both >80% and >90% 
of doses taken as measures by MEMS. The highest specificity was observed when 
the score of 0 was set as compliant and 1 or more as non-complaint for both 80% 
and 90% cutoff values for MEMS. The agreement with MEMS was highest when 
the score of 0 was set as complaint and 1 or more as non-complaint (K=0.16) for 
>80% compliance MEMS and (K=0.33) for >90% compliance MEMS indicating 
fair reliability. 
G) Comparison between MEMS and Temptation to skip medication scale 12 
(TEMP12). 
For this measure the total population was n=64. Three different cutoff scores were 
used to determine which one was the most useful. 
Table 22-24 and Tables 30-32: Shows the agreement between MEMS and 
Temptation to skip medication scale 12. The total score on the scale ranged from 
12-60. The highest sensitivity of 0.61 and 0.66 was seen when the score of 12, 13 
and 14 was set as compliant and the score of 15 and more as non-compliant for 
both >80% and >90% of doses taken as measured by MEMS respectively. The 
highest specificity of 0.68 and 0.64 was observed when the score of 12 was set as 
compliant and 13 or more as non-compliant for both 80% and 90% cutoff values 
for MEMS respectively. The agreement with MEMS was highest when the score 
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of 12 and 13 was set as complaint and 14 or more as non-compliant i.e. K=0.16 for 
>90% compliance MEMS. 
H) Comparison between MEMS and Temptation to skip medication scale 13 
(TEMP13). 
For this measure the total population was n=56. Two different cutoff scores were 
used to determine which one was the most useful. 
Table 25-26 and Tables 33-34: Shows the agreement between MEMS and 
Temptation to skip medication scale 13. The total score on the scale ranged from 
13-65. The highest sensitivity of 0.57 and 0.61 was seen when the score of 13 and 
the score of 14 was set as compliant and the score of 15 and more as non-
compliant for both >80% and >90% of doses taken as measured by MEMS 
respectively. The highest specificity of 0.68 and 0.64 was observed when the score 
of 13 was set as compliant and 14 or more as non-complaint for both 80% and 
90% cutoff values for MEMS respectively. The agreement with MEMS was 
highest at the when the score of 13 and 14 was set as compliant and 15 or more as 
non-complaint i.e. K=0.21 for >90% compliance, indicating fair reliability of the 
measure at this particular cutoff. 
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DISCUSSION 
There is little debate that adherence to treatment recommendations has a major impact 
on health outcomes and the cost of health care. For medications, the health effect of 
deviations from recommended therapy is a function of the pharmacological properties 
of the medication prescribed. The methods used to estimate adherence in research or 
practice must be sensitive variations in adherence that meaningfully affect health 
outcomes. 
Formal validation of the many alternative methods of adherence assessment has not 
been extensive. No published study has evaluated all these measures against electronic 
monitoring in the same population. 
In this study we examined the accuracy of various self-report measures of adherence 
with electronically monitored adherence. 
Number of doses missed in past one month: 
The results for the second measure i.e. numbers of doses missed in the past three 
months were very much similar to the first measure. The sensitivity was 100% 
indicating that the complaint patients were correctly classified, as being complaint, at 
the same time the specificity was zero, indicating that the non-compliant patients were 
incorrectly classified, as complaint. Therefore there was only a slight agreement 
between the compliance reported using this measure and MEMS report, indicating low 
reliability of this measure. 
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Number of doses missed in the past three months: 
The results for the second measure i.e. numbers of doses missed in the past three 
months were very much similar to the first measure. The sensitivity was 100% 
indicating that the complaint patients were correctly classified, as being complaint, at 
the same time the specificity was zero, indicating that the non-compliant patients were 
incorrectly classified as complaint. Therefore there was only a slight agreement 
between the compliance reported using this measure and MEMS report (K= 0.05 and 
0.03) indicating low reliability of this measure. 
Medication Adherence Scale: 
The third measure MAS was studied at three different cutoff scores, for both subsets 
of population i.e. patients on PI and patients on ART. 
In the PI population when the MAS was coded as, score of 0 as compliant and 1 or 
more as non-compliant, it underestimated adherence as compared to MEMS report and 
showed low sensitivity and high specificity. This indicated that the non-compliant 
patients were correctly classified as non-adherent, but at the same time the all the 
compliant patient were not correctly classified as compliant. Both the sensitivity and 
specificity were higher at ~ 90% compliance MEMS then at ~ 80% compliance 
MEMS, indicating greater accuracy at higher cutoff compliance values. The 
agreement of this measure was better with ~ 90% compliance MEMS (K=0.26) as 
compared to~ 80% compliance MEMS (K=0.31), indicating better reliability at 90% 
cutoff i.e. more stringent conditions. When the MAS was coded as, score of 0 and 1 as 
compliant and 2 or more as non-compliant, it showed good sensitivity compared to 
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specificity, indicating poor accuracy of this method, also greater accuracy was seen at 
90% cutoff as compared to 80%. The agreement with MEMS was fair (K=0.22) when 
compared with ~ 80% compliance MEMS and (K=0.25) with ~ 90% compliance 
MEMS. 
When the MAS was coded as, score of 0, 1 and 2 as compliant and 3 or more as non-
compliant, it showed a very high sensitivity and a low specificity leading to 
overestimation of compliance. The reliability and accuracy results were opposite at 
this level of compliance on MAS, the agreement at ~ 90% compliance MEMS 
(K=0.15) was lower than at~ 80% compliance MEMS, also the accuracy was lower at 
90% cutoff compared to 80%. This indicated that as compliance level become less 
stringent the accuracy and reliability of the measure decreases. 
In the patients with ART, when the MAS was coded as, score of 0 as compliant and 1 
or more as non-complaint, it showed a higher sensitivity as compared to specificity. 
Both the sensitivity and specificity was higher at ~ 90% compliance MEMS then at ~ 
80% compliance MEMS. The agreement of this measure with ~ 90% compliance 
MEMS (K=0.33) was greater then with~ 80% compliance MEMS (K=0.16). When 
the score of 0 and 1 was coded as compliant and 2 or more as non-compliant, it 
showed higher sensitivity and lower specificity as compared to the score of 0 as 
compliant and 1 or more as non-complaint. When the MAS scale was coded as, score 
of 0,1 and 2 as compliant and 3 or more as non-compliant, the measure showed 
highest sensitivity as compared to the other two cutoffs. A higher sensitivity was 
observed at 90% cutoff MEMS and compared with 80% cutoff MEMS. The reliability 
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of this measure was similar both at ~ 90% compliance MEMS and ~ 80% compliance 
MEMS i.e. 0.15. 
Temptation to skip medication scale 12: 
In patients on PI, when the TEMP 12 scale was coded as, score of 12 as compliant and 
13 or more as non-complaint this measure showed average sensitivity and specificity 
indicating fair accuracy of this measure, similar results were seen for both 80% and 
90% cutoff MEMS. But according to the kappa statistics agreement of this measure 
with MEMS was only slight indicating a poor reliability (K=0.11 and 0.06). 
For patients on ART, this measure was studied at three different cutoffs to determine 
which one is more useful. When the TEMP 12 scale was coded as, score of 12 as 
compliant and score of 13 or more as non-complaint, it showed lower sensitivity as 
compared to specificity. Indicating that the compliant patients were wrongly 
categorized as non-compliant. Thus indicating poor accuracy. There was a slight 
agreement with MEMS report both at ~ 80% compliance (K=0.16) and ~ 90% 
compliance. 
When the TEMP 12 scale was coded as, score of 12 and 13 as complaint and 14 or 
more as non-compliant, it showed average sensitivity and specificity, at ~ 90% 
compliance MEMS indicating good accuracy of this method. But the agreement with 
MEMS was slight both at 80% (0.19) and 90% cutoff (K=0.16). When the TEMP 12 
scale was coded as score of 12, 13 and 14 as complaint and 15 or more as non-
compliant, the reliability at ~80% compliance MEMS (K=0.18) was slight as 
compared to ~ 90% compliance MEMS (K=0.21), these kappa values indicated fair 
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agreement between the two measures i.e. temptation to skip medication scale and 
MEMS reported compliance. The sensitivity and specificity were higher at this level 
as compared to other two cutoffs. 
Temptation to skip medication scale 13: 
In patients on PI when the TEMP 13 scale was coded as, score of 13 as complaint and 
14 or more as non-complaint, the measured showed average sensitivity and specificity 
indicating fair accuracy of this measure. Similar results were seen for both 80% and 
90% cutoff MEMS at this cutoff value on TEMP 13 scale. At the same time the 
agreement of this measure with MEMS was only slight indicating a poor reliability. 
There was no difference in both the accuracy and reliability of temptation to skip 
medication 12 scale and temptation to skip medication 13 scale at both ~ 80% and ~ 
90% compliance measures by MEMS for this particular cutoff. 
For patients on ART this measure was studied at two different cutoffs to determine 
which one was more useful. When the TEMP 13 scale was coded as, score of 13 as 
compliant and 14 or more as non-complaint, it showed low sensitivity as compared to 
specificity. This indicated that the compliant patients were wrongly categorized as 
non-compliant. Thus indicating low accuracy. There was only a slight agreement 
between the MEMS reported compliance and this measure at both ~ 80% compliance 
MEMS (K=0.17) and ~ 90% compliance MEMS (K=0.18) according to the kappa 
statistics. 
When the TEMP 13 scale was coded as, score of 13 and 14 as compliant and 15 or 
more as non-complaint, it had average sensitivity and specificity (0.61), at ~ 90% 
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compliance MEMS indicating good accuracy of this method. The agreement with 
MEMS was fair (0.21) at ~ 90% compliance MEMS indicating average reliability. 
There was only slight agreement with MEMS report at 80% compliance MEMS 
(0.18). 
The ideal measure of compliance is the one, which has both, good sensitivity and 
specificity. For the patients on PI, MAS indicated to be a good measure of compliance. 
When the score was set as 0 as complaint and 1 or more as non-compliant, it showed 
both good accuracy and fair reliability. Temptation to skip medication had good 
accuracy but only slight reliability. 
For patients on ART, good accuracy and reliability was seen only at ~ 90% 
compliance MEMS. MAS subscale (score of 0 as complaint and 1 or more non-
compliant) had good sensitivity and specificity and also average reliability. 
Temptation to skip medication scale 13 indicated good accuracy at the same time had 
fair reliability. 
Limitations 
Generalizability: The study population was not randomly selected. This puts 
limitation on extrapolating the results for the entire population. The results of this 
study do not demonstrate the extent of discrepancies between the self-report and 
electronic measure of adherence as previously demonstrated in the literature. There are 
two possible explanations for these findings. First patients in this study were asked to 
document unintentional opening of their MEMS cap on the blank calendar dispensed 
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to them at the baseline. As a result, some patients documented missed doses or late 
doses, which may have increased their recall and self-report of non-adherence over 
previous month. Second, the adherence findings from the study are from a young, 
educated, and motivated population with very high degree of adherence, according to 
dose percentage calculations. It is possible that self-report, in general, may exceed 
MEMS report to a large extent in a markedly nonadherent population and to a lesser 
degree in a very adherent patient group. 
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CONCLUSION 
The objective of this study was to test the sensitivity, specificity and reliability of 
various self-report measures , considering MEMS report as the standard. 
Self-reported number of doses missed in the past one month and number of doses 
missed in the past three months overestimated adherence as compared to MEMS 
report. Both these self-report measures showed high sensitivity and low specificity, 
which indicated low accuracy of this measure. A probable reason for low accuracy 
may be recall memory errors such as forgetting (underreport) and telescoping 
(overestimation). 
It is also seen that in comparison to number of doses missed in the past one month, 
number of doses missed in the past three months had even lower accuracy and 
reliability, though not very significant. This might be due an even greater the recall 
bias, as the memory of the person becomes weaker over long period of time. 
These results were contradictory to a published report which found reported that self-
reports were more accurate measures than when number of missed doses was used to 
measure compliance (Chesney et al., 1999). 
Medication Adherence Scale was divided into three sub-categories to access 
compliance at various levels. It was observed that as the criteria for assessment 
became less stringent, more non-compliant patients were incorrectly categorized as 
compliant leading to decrease in the accuracy of the method. The reliability also 
decreased simultaneously. 
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Higher accuracy and reliability was obtained at the more (higher) stringent levels of 
compliance and MEMS ~ 90% compliance as compared with others. 
Overall this measure showed a fair agreement with the MEMS report at all higher 
cutoff points (stringent conditions). The reliability and the accuracy of this measure 
were better in the PI population than in the ART population. 
Temptation to skip medication scale was also broken down into sub categories to test 
compliance at various levels. Similar results as those for MAS were obtained, except 
for temptation to skip medication scale 13 (Score of 13 coded as compliant and 14 or 
more as non-compliant) were there was an increase in the reliability along with the 
increase in sensitivity and decrease in specificity. This might be due to setting up very 
high (stringent) levels of compliance, that even most of the compliant patients were 
classified as non-complaint. 
The addition of the additional question in temptation to skip medication scale 13 did 
not make a significant difference in the assessment of compliance. The results of these 
studies regarding the accuracy and reliability of self-report measures of medication 
adherence are disappointing, particularly given the reliance on self-report 
methodology among the clinical and research communities. 
The overall results of all the self-report measures were consistent with the literature on 
compliance that self-report methods consistently overestimate patient adherence 
(Cramer et al., 1989; Waterhouse et al., 1993). 
The study found that measuring compliance on continuous scales like MAS or 
temptation to skip medication scale, where the patients were asked about their general 
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attitude towards the medication regimen, are more accurate and reliable measures to 
detect compliance as compared with number of doses missed. Therefore, these scales 
could be further developed in future research to yield better measures to detect 
compliance. 
In general it was seen for all the measures, that when the criteria for compliance was 
set more stringent, it gave more accurate and reliable results. 
Additional studies will be required to replicate these findings in other HIV 
populations. 
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TABLE A: Demographics of population used N=86 
Dem02ra_p_hics N _(o/tl_ Mean snT Mintf Maxttt 
Age 
>= 25 yrs 0(0%) 2.8953 0.7825 2.0000 4.0000 
26-35 yrs 31 (36.05%) 
36-45 yrs 33 (38.37%) 
46-55_.r_rs 22 _(25.58°/tl_ 
SEX 
Males 75 (87.21%) 
- - - -Females 11_(12.79°/tl_ 
Race 
White, non-Hispanics 69 (80.23%) 1.6744 1.5219 1.0000 
Hispanics 3 (3.49%) 1.0000 
African American 3 (3.49%) 
Native American 6 (6.98%) 
Asian 0(0%) 
Others 5 (5.81%) 
Education 
> 12 yrs 14 (16.28%) 
12 yrs 34 (39.53%) 2.4186 0.9262 1.0000 4.0000 
13-15 yrs 26 (30.23%) 
16 +yrs 12 (13.95%) 
r Annual Income 
Less than $15,000. 45 (54.88%) 
$15000 to $24,000. 17 (20.73%) 2.0121 1.4271 1.0000 5.0000 
$25,000 to $34,000. 5 (6.10%) 
$35,000 to $44,000. 4 (4.88%) 
$45,000 or more 11 _(13.41 o/tl_ 
Current health status 
Excellent 9 (10.47%) 2.5581 0.8346 1.0000 4.0000 
Very Good 30 (34.88%) 
Good 37 (43.02%) 
Fair 10 (11.63%) 
Poor 0_(00/.tl_ 
T-Cell count 
<500 20 (23.81%) 2.1547 0.8572 1.0000 . 4.0000 
201-500 36 (42.86%) 
50-200 23 (27.38%) 
Less than 50 5_{5.95°/tl 
EmJ!loyment Status 
Employed 36 (41.86%) 1.4186 0.4962 1.0000 2.0000 
Unem_p_l«!Y_ed 50 _(58.14 %1 
Insurance 
No insurance 82 (95.35%) 1.0465 0.2118 1.0000 2.0000 
Some insurance 4_(4.65%l 
snt: Standard deviation. 
Mintt: Minimum 
Maxttt: Maximum 
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Table B: 
Self-report measures of adherence for patients on protease inhibitors. 
Nos. Self-report measures N Mean snt Mintt Maxttt 
I. Number of doses missed in past one 72 1.60855 2.48843 0 12 
month. 
~ 2. Number of doses missed in past three 71 3.57746 5.38957 0 30 
...... 
months. 
3. Medication Adherence Scale. 71 1.09859 1.28901 0 6 
4. Tem.ptation to skip medication scale 12 68 16.3235 8.01387 12 60 
5. T~mptation to skip medication scale 13 68 17.7941 8.81748 13 65 
snt: Standard deviation. 
Min tt: Minimum 
Maxttt: M~r.imum 
~ 
N 
Table C: 
Self-report measure of adherence for patients on anti-retroviral therapy. 
Nos. Self-report measures N Mean snt Mintt Maxttt 
1. Medication Adherence Scale 64 0.8437 0.9955 0 4 
2. Temptation to skip 59 15.745 5.2966 12 33 
medication 12 
3. Temptation to skip 58 17.086 5.9773 13 38 
medication 13 
-
snt: Standard deviation. 
Min tt: Minimum 
Max ttt: Maximum 
.j:::. 
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TABLED: 
Compliance coding strategies for patients on protease inhibitors. 
Coding 
Self-re_1>_ort measures O=tc and l=ttNc N_{_%}_ Mean 
1)% of doses missed in past 
one month. 
a. OMl ~ 80%=0 and < 80%= 1. 72 0 
b.OM2 ~ 90%=0 and < 90%= 1. 72 0.02777 
2) % of doses missed in past 
3 months. 
a. TMl ~ 80%=0 and< 80%=1 . 71 0 
b. TM2 ~ 90%=0 and < 90%= 1. 71 0.01408 
3) Medication Adherence 
Scale (MAS) 0-6 
a. PIMl 0 = 0 and 1 + = 1. 71 0.57746 
b. PIM2 0 and l=O and 2+ = 1. 71 0.30985 
c. PIM3 0,1 and 2= 0 and 3+ = 1. 71 0.12676 
4) Temptation to skip 
medication Scale 12 (12-60) 
a. PI12TI 12 = 0 and 13+ = 1. 68 0.51470 
5) Temptation to skip 
medication Scale 13 (13-65) 
b. PI13TI 13= 0 and 14+ = 1. 68 0.51470 
tC= Compliant and TfNc =Non Compliant 
SDt: Standard deviation. 
Mintt: Minimum 
Max ttt: Maximum . 
..., 
snt Mintt Maxttt 
0 0 0 
0.1654 0 1 
0 0 0 
0.11867 0 1 
0.49747 0 1 
0.46572 0 1 
0.33507 0 1 
0.50349 0 1 
0.50349 0 1 
..j::.. 
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TABLE E: 
Compliance coding strategies for patients on Anti-retroviral therapy. 
Self-report measures Coding N Mean 
O=tc and l=ttNc 
1) Medication Adherence 
Scale (MAS) 0-6 
a.AVMl 0 = 0 and 1 + = 1. 71 0.57746 
b.AVM2 0 and 1=0 and 2+ = 1. 71 0.30985 
c. AVM3 0,1 and 2= 0 and 3+ = 1. 71 0.12676 
2) Temptation to skip 
medication Scale 12 (12-60) 
a. AV12TI 12=0andl3+=1. 68 0.51470 
b. AV12T2 12 and 13 = 0 and 14+ = 1. 
c. AV12T3 12, 13and14=0and 15+= 1 
3) Temptation to skip 
medication Scale 13 (13-65) 
a. AV13TI 13= 0 and 14+ = 1. 68 0.51470 
b.AV13T2 13 and 14 = 0 and 15+ = 1. 
c. AV13T3 13, 14 and 15 = 0 and 16+ = 1 
tC= Compliant and t1Nc =Non Compliant 
SD t: Standard deviation. 
Min tt: Minimum 
Max ttt: Maximum 
snt Mintt Maxttt 
0.49747 0 1 
0.46572 0 1 
0.33507 0 1 
0.50349 0 1 
0.50349 0 1 
.+:>. 
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TABLE F: 
Compliance coding strategies for MEMS data for patients on protease inhibitors. 
MEMS Measures Coding N Mean snt Mintt 
O=tc and l=ttNc 
1) Gold Standard I 
MEMS 1 ~ 80%=0 and< 80%=1. 64 0.34375 0.47871 0 
2) Gold Standard II 
MEMS2 ~ 90%=0 and < 90%= 1. 64 0.48437 0.50370 0 
tC= Compliant and ttNc =Non Compliant 
snt: Standard deviation. 
Mintt: Minimum 
Max ttt: Maximum 
'· 
Maxttt 
1 
1 
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TABLEG: 
Compliance coding strategies for MEMS data for patients on Anti-retroviral therapy. 
MEMS Measures Coding N Mean snt Mintt 
O=tc and l=ttNc 
1) Gold Standard I 
MEMS 1 ~ 80%=0 and< 80%=1. 64 0.34375 0.47871 0 
2) Gold Standard II 
MEMS2 ~ 90%=0 and < 90%= 1. 64 0.48437 0.50370 0 
tC= Compliant and ttNc =Non Compliant 
snt: Standard deviation. 
Mintt: Minimum 
Max ttt: Maximum 
Maxttt 
1 
1 
-+>-
-....] 
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TABLEH: 
Sensitivity, Specificity and Kappa statistics for various Self-report measures for patients on Protease 
inhibitors. ~ 80°/o Compliance by MEMS (Gold Standard I) 
Nos. J_ Self-report measures 
1 , . #of doses missed in past one month 
( ~ 80%=Ct & <80%=ttNC) 
2 # of doses missed in one past month 
(~ 90%=C t & <90%=ttNC) 
3 # of dosed missed in past three months 
(~ 80%=Ct & <80%dtNC) 
4 # of doses missed in three past month 
(~ 90%=C t & <90%=ttNC) 
5 Medication Adherence Scale 
(O=Ct & l+=ttNC) 
6 Medication Adherence Scale 
(0 & l=Ct & 2+dtNC) 
7 Medication Adherence Scale 
(0,1&2=Ct & 3+dtNC) 
8 Temptation to skip medication scale 12 
(12=Ct &13+dtNC) 
9 Temptation to skip medication scale 13 
(13=Ct &14+=ttNC) 
t C= Compliant 
ttNC= Noncompliant 
Sensitivity 
1.00 
1.00 
1.00 
1.00 
0.53 
0.77 
0.96 
0.52 
0.52 
Specificity Expected Observed Kappa 
a_g_reement a_g_reemen t 
0.00 0.69 0.69 0.00 
0.10 0.72 0.72 0.13 
0.00 0.69 0.69 0.00 
0.05 0.69 0.71 0.06 
0.80 0.61 0.61 0.26 
0.45 0.67 0.67 0.22 
0.35 0.78 0.78 0.37 
0.61 0.55 0.55 0.11 
0.61 0.55 0.55 0.11 
.i:. 
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TABLE I: 
Sensitivity, Specificity and Kappa statistics for various Self-report measures for patients on Protease 
inhibitors. ~ 90°/o Compliance by MEMS (Gold Standard in 
Nos. I Self-report measures 
1 # of doses missed in past one month 
(~ 80%=C t & <80%dtNC) 
2 # of doses missed in one past month 
(~ 90%=C t & <90%=ttNC) 
3 # of dosed missed in past three months 
(~ 80%=Ct & <80%=ttNC) 
4 #of doses missed in three past month 
(~ 90%=C t & <90%=ttNC) 
5 Medication Adherence Scale 
(O=Ct & l+=ttNC) 
6 Medication Adherence Scale 
(0 & l=Ct & 2+=ttNC) 
7 Medication Adherence Scale 
(0,1&2=Ct & 3+=ttNC) 
8 Temptation to skip medication scale 12 
(12=C t &13+=ttNC) 
9 Temptation to skip medication scale 13 
(13=Ct &14+=ttNC) 
t C= Compliant 
ttNC= Noncompliant 
Sensitivity Specificity 
1.00 0.00 
1.00 0.06 
1.00 0.00 
1.00 0.03 
0.59 0.73 
0.82 0.42 
0.94 0.21 
0.52 0.55 
0.52 0.55 
Expected Observed Kappa 
a_greement a_g_reement 
0.50 0.50 0.00 
0.50 0.53 0.06 
0.50 0.50 0.00 
0.50 0.51 0.03 
0.50 0.66 0.31 
0.50 0.63 0.25 
0.51 0.58 0.15 
0.50 0.53 0.06 
0.50 0.53 0.06 
.+:>. 
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TABLEJ: 
Sensitivity, Specificity and Kappa statistics for various Self-report measures for patients on Anti-
retroviral therapy. ~ 80°/o Compliance by MEMS (Gold Standard I) 
Nos. Self-report measures 
1 Medication Adherence Scale 
_{_O=tc & l+=ttNC} 
2 Medication Adherence Scale 
J_O & l=tc & 2+=ttNC) 
3 Medication Adherence Scale 
J_0,1 &2=tc & 2+=ttNC)_ 
4 Temptation to skip medication 
scale 12 _(_12=tc &13+=ttNCl 
5 Temptation to skip medication 
scale 12 (12 & 13=tc &14+=ttNC) 
6 Temptation to skip medication 
scale 12 _{_12,13&14=tc&15+=ttNCl 
7 Temptation to skip medication 
scale 13 _{_13=tc &14+=ttNCl 
8 Temptation to skip medication 
scale 13 _(_13 & 14=tc &15+=ttNc_1 
' C• COmJ!l11ni 
"NC:• NonDOltll'llllflt 
Sensitivity 
0.51 
0.83 
0.98 
0.50 
0.55 
0.61 
0.51 
0.57 
Specificity Expected Observed Kappa 
a2reement a~eement 
0.67 0.48 0.56 0.16 
0.29 0.59 0.65 0.13 
0.14 0.64 0.69 0.15 
0.68 0.48 0.56 0.16 
0.63 0.50 0.58 0.16 
0.47 0.53 0.56 0.07 
0.68 0.48 0.57 0.17 
0.63 0.50 0.59 0.18 
~, 
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TABLE K: 
Sensitivity, Specificity and Kappa statistics for various Self-report measures for patients on Anti-
retroviral therapy.~ 90o/o Compliance by MEMS (Gold Standard II) 
Nos. Self-report measures 
1 Medication Adherence Scale 
J_O=tc & l+=ttNCl 
2 Medication Adherence Scale 
J_O & l=tc & 2+=ttNCJ_ 
3 Medication Adherence Scale 
_i0,1 &2=tc & 2+=ttNCJ_ 
4 Temptation to skip medication 
scale 12 J_12=tc &13+=ttNCJ_ 
5 Temptation to skip medication 
scale 12 _Q.2 & 13=tc &14+=ttNCl 
6 Temptation to skip medication 
scale 12 J_l2,13&14=tc&l5+=ttNCl 
7 Temptation to skip medication 
scale 13 _i13=tc &14+=ttNC1 
8 Temptation to skip medication 
scale 13 _Q.3 & 14=tc &15+=ttNCl 
t C= Compliant 
ttNC= Noncompliant 
Sensitivity 
0.61 
0.88 
1.00 
0.52 
0.59 
0.66 
0.54 
0.61 
Specificity Expected Observed Kappa 
a_g_reement a_g_reement 
0.72 0.50 0.66 0.33 
0.31 0.52 0.61 0.20 
0.14 0.53 0.60 0.15 
0.64 0.50 0.58 0.16 
0.61 0.50 0.60 0.19 
0.50 0.50 0.58 0.16 
0.64 0.50 0.59 0.18 
0.61 0.50 0.61 0.21 
Vi 
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Table 1: 
Agreement between Gold Standard I (~ 80%, compliance MEMS) and Self-report measure # 1 (~ 
80%, of doses taken in past one month) for patient population on protease inhibitor. 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
~ 80% compliance(~ 80% I 47 I 21 I 68 
of doses taken in the past 
SELF-REPORT one month) 
< 80% compliance (~ 80% f 0 I 0 I 0 
of doses taken missed the 
past one month) 
Total 47 21 68 
Sensitivity= 47/47 * 100 = 100% 
Specificity = 0/21 * 100 = 0% 
Vl 
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Table 2: 
Agreement between Gold Standard I(~ 80°/o compliance MEMS) and Self-report measure# 2 (~ 
90°/o of doses taken in past one month) for patient population on protease inhibitor. 
~ 90% compliance (~ 90% 
of doses taken in the past 
SELF-REPORT one month) 
< 90% compliance (~ 90% 
of doses missed in the past 
one month) 
Total 
MEMS 
:2: 80% Compliant < 80% Noncompliant 
47 19 
0 2 
47 21 
Sensitivity= 47/47 * 100 = 100% 
Specificity = 2/21 * 100 = 10% 
Total 
66 
2 
68 
Ul 
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Table 3: 
Agreement between Gold Standard I(~ 80%> compliance MEMS) and Self-report measure# 3 (~ 
80°/o of doses taken in past three months) for patient population on protease inhibitor. 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
~ 80% compliance (~ 80% I 47 I 20 I 67 
of doses taken in the past 
SELF-REPORT three months) 
< 80% compliance (~ 80% I 0 I 1 I 1 
of doses missed in the past 
three months) 
Total 47 21 68 
Sensitivity= 47/47 * 100 = 100% 
Speci~city = 1121 * 100 = 5% 
Vl 
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Table 4: 
Agreement between Gold Standard I(:?: 80°/o compliance MEMS) and Self-report measure# 4 (:?: 
90°/o of doses taken in past three months) for patient population on protease inhibitor. 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
:?: 90% compliance (:?: 90% I 47 I 21 I 68 
of doses taken in the past 
SELF-REPORT three months) 
< 90% compliance (:?: 90% 
~ .. 
0 I 0 I 0 
of doses missed in the past 
three months) 
Total 47 21 68 
Sensitivity= 47/47 * 100 = 100% 
Specificity= 2/21 * 100 = 10% 
Vl 
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Table 5: 
Agreement between Gold Standard I(~ 80°/o compliance MEMS) and Self-report measure #5 
(Medication Adherence Scale) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Medication Adherence Scale 
o = tc 
Medication Adherence Scale 
1+ = ttNc 
Total 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
25 4 29 
22 16 38 
47 20 67 
Sensitivity= 25/47 * 100 = 53% 
Specificity = 16/20 * 100 = 80% 
Vl 
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Table 6: 
Agreement between Gold Standard I(:?: 80°/o compliance MEMS) and Self-report measure #6 
(Medication Adherence Scale) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNC= Noncompliant 
Medication Adherence Scale 
0 and 1= tc 
Medication Adherence Scale 
2+ = ttNc 
Total 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
36 11 
·~ 
47 
~ 
11 9 20 
47 20 67 
Sensitivity= 36/47 * 100 = 77% 
Specificity = 9120 * 100 = 45% 
Vl 
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Table 7: 
Agreement between Gold Standard I (~ 80o/o compliance MEMS) and Self-report measure # 7 
(Medication Adherence Scale) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNC= Noncompliant 
Medication Adherence Scale 
0 1and2= tc 
' 
Medication Adherence Scale 
3+ = ttNc 
Total 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
45 13 58 
2 7 9 
47 20 67 
Sensitivity= 45/47 * 100 = 96% 
Specificity = 7120 * 100 = 35% 
-
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Table 8: 
Agreement between Gold Standard I (~ 90°/o compliance MEMS) and Self-report measure #8 
(Temptation to skip medication scale 12) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Temptation to skip medication 
Scale 12 
12 = tc 
Temptation to skip medication 
Scale 12 
13+ = ttNc 
Total 
I 
I 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
24 I 7 I 31 
22 I 11 I 33 
46 18 64 
Sensitivity== 24146 * 100 = 52% 
Specificity:;: 11/18 * 100 = 61 % 
Vl 
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Table 9: 
Agreement between Gold Standard I (~ 90°/o compliance MEMS) and Self-report measure #9 
(Temptation to skip medication scale 13) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Temptation to skip medication 
Scale 13 
13= tc 
Temptation to skip medication 
Scale 13 
14+ = ttNc 
Total 
I 
I 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
24 I 7 I 31 
22 I 11 I 33 
46 18 64 
Sensitivity = 24/46 * 100 = 52% 
Specificity= 11/18 * 100 = 61 % 
O'\ 
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Table 10: 
Agreement between Gold Standard II(;::: 90o/o compliance MEMS) and Self-report measure# 1 (;::: 
80% of doses taken in past one month) for patient population on protease inhibitor. 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
;::: 80% compliance ( ;::: I 34 I 34 I 68 
80% of doses taken in the 
past one month) 
SELF-REPORT 
< 80% compliance (<'. 80% I 0 I 0 I 0 
of doses taken missed the 
past one month) 
Total 34 34 68 
Sensitivity = 34/34 * 100 = 100% 
Specificity = 0/34 * I 00 = 0% 
---.. 
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Table 11: 
Agreement between Gold Standard II(~ 90% compliance MEMS) and Self-report measure# 2 (~ 
90o/o of doses taken in past one month) for patient population on protease inhibitor. 
~ 90% compliance (~ 
90% of doses taken in the 
SELF-REPORT past one month) 
< 90% compliance (~ 90% 
of doses taken missed the 
past one month) 
Total 
MEMS 
~ 90% Compliant < 90% Noncompliant 
34 32 
0 2 
34 34 
Sensitivity= 34/34 * 100 = 100% 
Specificity = 2/34 * I 00 = 6% 
Total 
66 
2 
68 
0\ 
N 
Table 12: 
Agreement between Gold Standard II(~ 90°/o compliance MEMS) and Self-report measure# 3 (~ 
80°/o of doses taken in past three months) for patient population on protease inhibitor. 
MEMS 
;;;: 90% Compliant < 90% Noncompliant Total 
~ 80% compliance (~ 80% I 34 I 34 I 68 
of doses taken in the past one 
month) 
SELF-REPORT 
< 80% of doses taken in the I 0 I 0 I 0 
past three months=ttNc 
Total 34 34 68 
Sensitivity = 34/34 * 100 = 100% 
Specificity = 0/34 * 100 = 0% 
°' w 
Table 13: 
Agreement between Gold Standard II(~ 90°/o compliance MEMS) and Self-report measure# 4 (~ 
90o/o of doses taken in past three months) for patient population on protease inhibitor. 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
~ 90% compliance c~ 90% I 34 I 33 I 67 
of doses taken in the past one 
month) 
SELF-REPORT 
< 90% of doses taken in the I 0 I 1 I 1 
past three months=ttNc 
Total 34 34 68 
Sensitivity = 34/34 * 100 = 100% 
Specificity= 1/34* 100 = 3% 
0\ 
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Table 14: 
Agreement between Gold Standard II(;:::: 90%> compliance MEMS) and Self-report measure# 5 
(Medication Adherence Scale) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Medication Adherence Scale 
o=tc 
Medication Adherence Scale 
l+=ttNc 
Total 
I 
I 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
20 I 9 I 29 
14 I 24 I 38 
34 33 67 
Sensitivity = 20/34 * 100 = 59% 
Specificity= 24/33 * 100 = 73% 
-, 
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Table 15: 
Agreement between Gold Standard II(~ 90% compliance MEMS) and Self-report measure# 6 
(Medication Adherence Scale) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Medication Adherence Scale 
o and 1= tc 
Medication Adherence Scale 
2+=ttNc 
Total 
I 
I 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
28 
I 
19 
I 
47 
6 I 14 I 20 
34 33 67 
Sensitivity= 28/34 * 100 = 82% 
Specificity= 14/33 * 100 = 42% 
..... \ 
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Table 16: 
Agreement between Gold Standard II(~ 90%, compliance MEMS) and Self-report measure# 7 
(Medication Adherence Scale) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNC= Noncompliant 
Medication Adherence Scale 
0 1and2=tc 
' 
Medication Adherence Scale 
3+=ttNc 
Total 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
32 26 58 
2 7 9 
34 33 67 
Sensitivity= 32/34 * 100 = 94% 
Specificity = 3317 * 100 = 21 % 
°' -...) 
Table 17: 
Agreement between Gold Standard II(~ 90°/o compliance MEMS) and Self-report measure# 8 
(Temptation to skip medication scale 12) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNC= Noncom pliant 
Temptation to skip medication 
Scale 12 
12=tc 
Temptation to skip medication 
Scale 12 
13+=ttNc 
Total 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
17 14 31 
16 17 33 
33 31 64 
Sensitivity = 17 /3 3 * 100 = 52 % 
Specificity = 14/31 * 100 = 55% 
~ -
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Table 18: 
Agreement between Gold Standard II (~ 90%> compliance MEMS) and Self-report measure # 9 
(Temptation to skip medication scale 13) for patients on Protease Inhibitor. 
SELF-REPORT 
t C= Compliant 
ttNe= Noncompliant 
Temptation to skip medication 
Scale 13 
13=tc 
Temptation to skip medication 
Scale 13 
14+=ttNc 
Total 
I 
I 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
17 I 14 I 31 
16 I 17 I 33 
33 31 64 
Sensitivity= 17/33 * 100 = 52% 
Specificity = 17 /31 * 100 = 55% 
,..---
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Table 19: 
Agreement between Gold Standard I(~ 80°/o compliance MEMS) and Self-report measure# 1 
(Medication Adherence Scale) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Medication Adherence Scale 
o=tc 
Medication Adherence Scale 
l+=ttNc 
Total 
I 
I 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
21 I 7 I 28 
20 I 14 I 34 
41 21 62 
Sensitivity = 21/41 * 100 = 51 % 
Specificity = 14/21 * 100 = 67% 
-., 
,.,--. 
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Table 20: 
Agreement between Gold Standard I (~ 80°/o compliance MEMS) and Self-report measure # 2 
(Medication Adherence Scale) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNC= Noncompliant 
Medication Adherence Scale 
o and 1= tc 
Medication Adherence Scale 
2+=ttNc 
Total 
I 
I 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
34 
I 
15 
I 
49 
7 I 6 I 13 
41 21 62 
Sensitivity= 34/41 * 100 = 83% 
Specificity = 6/21 * 100 = 29% 
-....) 
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Table 21: 
Agreement between Gold Standard I(~ 80% compliance MEMS) and Self-report measure# 3 
(Medication Adherence Scale) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Medication Adherence Scale 
o 1and2=tc ,
Medication Adherence Scale 
3+=ttNc 
Total 
I 
I 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
40 I 18 I 58 
1 I 3 I 4 
41 21 62 
Sensitivity= 40/47 * 100 = 98% 
Specificity= 3/21 * 100 = 14% 
-....) 
N 
Table 22: 
Agreement between Gold Standard I (~ 80°/o compliance MEMS) and Self-report measure # 4 
(Temptation to skip medication scale 12) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNC= Noncompliant 
Temptation to skip medication 
Scale 12 
12=tc 
Temptation to skip medication 
Scale 12 
13+=ttNC 
Total 
I 
I 
MEMS 
;;:: 80% Compliant < 80% Noncompliant Total 
19 I 6 I 25 
19 I 13 I 32 
38 19 57 
Sensitivity = 19/38 * 100 = 50% 
Specificity = 13/19 * 100 = 68% 
-...) 
VJ 
Table 23: 
Agreement between Gold Standard I(~ 80°/o compliance MEMS) and Self-report measure# 5 
(Temptation to skip medication scale 12) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNC=;o Noncompliant 
Temptation to skip medication 
Scale 12 
12 andl3=tc 
Temptation to skip medication 
Scale 12 
14+=ttNc 
Total 
I 
I 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
21 I 7 I 28 
17 I 12 I 29 
38 19 57 
Sensitivity= 21/38 * 100 = 55% 
Specificity= 12/19 * 100 = 63% 
...... 
-....) 
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Table 24: 
Agreemeut between Gold Standard I(;?: 80%> compliance MEMS) and Self-report measure# 6 
(Temptation to skip medication scale 12) for patients on Anti-retroviral. 
SELF-REP( 1RT 
t C= Complian' 
ttNc= Noncon pliant 
Temptation to skip medication 
Scale 12 I 
12, 13 and 14=tc 
Temptation to skip medication 
Scale 12 I 
15+=ttNc 
Total 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
23 I 10 I 33 
15 I 9 I 24 
38 19 57 
Sensitivity= 23/38 * 100 = 61 % 
Specificity = 9/19* 100 = 47% 
--..... 
-....) 
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Table 25: 
Agreement between Gold Standard I(~ 80°/o compliance MEMS) and Self-report measure# 7 
(Temptation to skip medication scale 13) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Temptation to skip medication 
Scale 13 
13=tc 
Temptation to skip medication 
Scale 13 
14+=ttNc 
Total 
I 
I 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
19 I 6 I 25 
18 I 13 I 31 
37 19 56 
Sensitivity = 19/37 * 100 = 51% 
Specificity= 13/19 * 100 = 68% 
-...) 
0\ 
Table 26: 
Agreement between Gold Standard I (~ 80%> compliance MEMS) and Self-report measure # 8 
(Temptation to skip medication scale 13) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNc= Nonc.:ompliant 
Temptation to skip medication 
Scale 13 
13and 14=tc 
Temptation to skip medication 
Scale 13 
15+=ttNc 
Total 
I 
I 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
21 I 7 I 28 
16 I 12 I 28 
37 19 56 
Sensitivity= 21/37 * 100 = 57% 
Specificity= 12/19 * 100 = 63% 
-..J 
-..J 
Table 27: 
Agreement between Gold Standard II(~ 90%> compliance MEMS) and Self-report measure# 1 
(Medication Adherence Scale) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Medication Adherence Scale 
o=tc 
Medication Adherence Scale 
l+=ttNc 
Total 
I 
I 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
20 
I 
8 
I 
28 
13 I 21 I 34 
33 29 62 
Sensitivity= 20/33 * 100 = 61 % 
Specificity= 21/29 * 100 = 72% 
-..I 
00 
,,---
Table 28: 
Agreement between Gold Standard II(~ 90%> compliance MEMS) and Self-report measure h 2 
(Medication Adherence Scale) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Medication Adherence Scale 
o and 1= tc 
Medication Adherence Scale 
2+=ttNc 
Total 
MEMS 
;;:: 90% Compliant < 90% Noncompliant Total 
29 20 49 
4 9 13 
33 29 62 
Sensitivity = 29/33 * 100 = 88% 
Spec.ificity = 9/29 * 100 = 31 % 
-. 
--....) 
\0 
Table 29: 
Agreement between Gold Standard II(~ 90°/o compliance MEMS) and Self-report measure# 3 
(Medication Adherence Scale) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNC= Noncompliant 
Medication Adherence Scale 
0 1and2=tc 
' 
I 
Medication Adherence Scale 
3+=ttNc I 
Total 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
33 I 25 I 58 
0 I 4 I 4 
33 29 62 
Sensitivity= 33/33 * 100 = 100% 
Specificity= 4/29 * 100 = 14% 
00 
0 
Table 30: 
Agreement between Gold Standard II(~ 90%, compliance MEMS) and Self-report measure# 4 
(Temptation to skip medication scale 12) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNC= Nancompliant 
Temptation to skip medication 
Scale 12 
12=tc 
Temptation to skip medication 
Scale 12 
13+=ttNc 
Total 
I 
I 
MEMS 
::>: 90% Compliant < 90% Noncompliant Total 
15 I 10 I 25 
14 I 18 I 32 
29 28 57 
Sensitivity= 15/29 * 100 = 52% 
Specificity = 18/28 * 100 = 64 % 
- .... 
00 
Table 31: 
Agreement between Gold Standard II(~ 90°/o compliance MEMS) and Self-report measure# 5 
(Temptation to skip medication scale 12) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Temptation to skip medication 
Scale 12 
12 and13=tc 
Temptation to skip medication 
Scale 12 
14+=ttNc 
Total 
I 
I 
MEMS 
;:.: 90% Compliant < 90% Noncompliant Total 
17 I 11 I 28 
12 I 17 I 29 
29 28 57 
Sensitivity = 17 /29 * 100 = 59% 
Specificity= 17 /28 * 100 = 61 % 
"'"""' 
00 
N 
Table 32: 
Agreement between Gold Standard II(~ 90% compliance MEMS) and Self-report measure# 6 
(Temptation to skip medication scale 12) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNc= Noncompliant 
Temptation to skip medication 
Scale 12 
12, 13 and 14=tc 
Temptation to skip medication 
Scale 12 
15+=ttNc 
Total 
I 
I 
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
19 I 14 I 33 
10 I 14 I 24 
29 28 57 
Sensitivity = 19/29 * 100 = 66% 
Specificity = 14/28 * 100 = 50% 
-, 
00 
VJ 
Table 33: 
Agreement between Gold Standard II(~ 90% compliance MEMS) and Self-report measure# 7 
(Temptation to skip medication scale 13) for patients on Anti-retroviral. 
SELF-REPORT 
t C= Compliant 
ttNC= Noncompliant 
Temptation to skip medication 
Scale 13 
13=tc 
Temptation to skip medication 
Scale 13 
14+=ttNc 
Total 
I 
I 
'--
MEMS 
~ 80% Compliant < 80% Noncompliant Total 
15 I 10 I 25 
13 I 18 I 31 
28 28 56 
Sensitivity = 15/28 * 100 = 54 % 
Specificity = 18/28 * 100 = 64 % 
00 
~ 
Table 34: 
Agreement between Gold Standard II (~ 90°/o compliance MEMS) and Self-report measure# 8 
(Temptation to skip medication scale 13) for patients on Anti-retroviral. 
Temptation to skip medication 
Scale 13 
13and 14=tc 
S1~LF-REPORT Temptation to skip medication 
Scale 13 
t C= Compliant 
ttNC= Noncompliant 
15+=ttNc 
Total 
MEMS 
~ 90% Compliant < 90% Noncompliant Total 
17 11 28 
11 17 28 
28 28 56 
Sensitivity = 17 /28 * 100 = 61 % 
Specificity= 17 /28 * 100 = 61 % 
' 
( 
( 
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APPENDIX 
• Questionnaire 
• SAS Program 
88 
Managing Your Medications Questionnaire 
Pltast answtr tht following questions thoughifully and complutly. This qutstionnain is about 
haw :you think andftd about the HIV relattld medications thal you ar1 taking, and about th• difftrenJ 
strolegies that people use to tab their mtdicadons. When you tum it in, w• will give you a gift ctrtifical11 
for$20tothankyoufor:yourparticipalian. 
PATIENT ID:-----
CODE FOR THIS Ql)ESTIONNAIRE: 
A) What an the first 3 luters of your mothu's frm name 1 
B) Whet!: your birtl: date! OOtCJOJCJO 
SECTION I 
BACKG~pUND INFORMATION 
Thtfirst section of this questionnaire asks about your background. 
::::> Please drde or fill in the correct response for each question. 
1. What is your age? 00ycars 
2. What is your gender? M F 
3. How would you describe your current health status? (Please check one answer) 
0 Excellent 0 Very Good 0 Good 0 Fair 0 Poor 
4. Which of the following best describes your ethnic background? 
0 White. non-Hispanic 
0 Native American 
0 Hispanic 
0 Asian 
5. How many years of education have yoo finished? 
(for example, for high school, fill in ·1r) 
6. Do you currently work either part-time or full time'? 
0 African American 
0 Other 
DO 
0 Full-time 0 Pan-time 0 I am not currently employed 
Uniwnlry of 11:Jtod6 b'4nd. t:>l99d 
89 
7. Do you live by yourself or with other people? 
0 Bymyself 0 With others 
8. If you live with others, how many (besides you) arc in your household? 00 
9. If you live with others, what is their relationship to you? (ChecJ: aU lha1 apply) 
0 Husband or wife 
0 Intimate partner 
D Other adults 18 or older 
0 Parents 
0 Grandparents 
0 Children under age 18 
0 Children over age iii 
10. Do you have any children'? If so, how many? (If none, pul 0) DD 
11. Do any of your adult children live nearby (within a half hour drive)? 
D Yes D No 0 Not applicable 
12. How many of your family or friends can you count on for emotional support? DD 
13. How many of your family or friends can you count on for financial help? DD 
14. How many of your family or friends can you count on for physical assistance, 
or a place to stay? DO 
15. Do you feel confident that your family or friends will continue to help you with your everyday needs? 
D Very confident 
0 Fairly confident 
D Somewhat confident 
D Less than somewhat confident 
D Not at all confident 
16. If you were to need more help with every day needs, do you feel confident that your family or friends 
could provide it7 
D Very confident 
D Fairly confident 
D Somewhat confident 
·O Less than somewhat confident 
D Not at all confident 
17. How many of your family & friends have you told about your HIV infection'? 
0 None D Less than half 0 About half 0 More than half D All 
90 
18. What type of health insurance coverage do you currently have7 
D NONE 
0 Rhode Island Elderly Assis~cc Program 
0 Blue Cross 0 Harvard Pilgrim Health Care (RIGHA, HCHP) 
0 Ocean State 0 Other private insurer 0 Medicare 
D VA 0 Other 0 Medicaid 
19. Which of the following best estimates yoor total (family) income during the past 12 months? 
D Less than s15,ooo 
D s1s,ooo to $24,ooo 
D m.ooo to S34,ooo 
D S35,ooo to S44,ooo 
0 $45,000 or more 
20. About how far do you live from this treatment center? 
0 Within walking distance 
0 Within a ten minute drive or less 
0 Within a twenty minute drive or· less 
0 Within a thirty minute drive 
0 More than thirty minutes away 
.... 
21. When you have questions about medications for ycur HIV infection, who do you usually ask7 
(P~ase check all that apply) • 
0 Pharmacist 
D Physician 
0 Social Worker 
0 Nurse 
0 Other persons with HIV infection 
0 Family members 
0 Friends D Other; please specify ___________ _ 
22. Which health care provider is most helpful to you in taking your medications as directed? 
0 Nurse 
0 Pharmacist 
0 Physician 
0 Social Worker 
D Other, please specify ___________ _ 
23. Is there someone living with you or close to you who helps or reminds you to take your medications on 
time7 
D Yes D No 
91 
24. How much bodily pain have you had during the past four w~lcs7 
0 None 
0 Very mild 
D Mild 
0 Moderate 
0 Seven: 
0 Very Severe 
25. During the past 4 weeks, how much did HN-rclated symptoms interfere with your normal work 
(including both work outside the home and housework}? 
0 Not at all 0 A little bit 0 Moderately 0 Quite a bit 0 Extrcme.ly 
26. During the past two weeks, how many days did you stay in bed all or most of the day'l 00 
27. How many times have you been hospitalized in the past year'? (If none, put 0) 00 
28. These questions are about how you feel and bow things have been with you during the past 4 weeks. 
::::> For each question, please give w one ~r rhal conus closest to the way you have been 
feeling. How 11Uldi of w ~ dwing w past 4 wulc:r ... 
NONE A.UT'rt.E SOME A.GOOD MOST A.LL 
OFTHI: BlTOl'Tlll or nm 11rrornm OFTIIE OFTIIE 
T1.'dE TINX TIME TIME TIME TIME 
a. Did you feel full of pep? 0 0 0 0 0 0 
b. Have you been a very nervous 0 0 0 0 0 0 
person? 
c. Have you felt so down iii the dumps 0 0 0 0 0 0 
that nothing could cheer you up? 
d. Have you felt calm and peaceful? 0 0 0 0 0 0 
e. Did you have a lot of energy? 0 0 0 0 0 0 
f. Have you felt downhearted and blue? 0 0 0 0 0 0 
g. Did you feel worn out? 0 0 0 0 0 0 
h. Have you been a happy person? 0 0 0 0 0 0 
i. Did you feel tired'? 0 0 D 0 0 0 
92 
29. How long ago were you diagnosed as HlV positive? 
0 Less than a month 
0 One to six months 
0 More than six months, but less than a year 
30. How do you think. you got your HIV infection? 
Please chuk all that apply 
0 Injection (IV) drug use 
0 ·Heterosexual contact 
0 Homosexual contact 
0 Blood transfusion 
0 Other: --------
0 l to2 years 
0 3 to4years 
0 S years or more 
31. What was your T cell count (CD4 count) the last time you were tested7 
0 Greater than 500 0 201-500 0 50-200 
93 
0 Less than 50 
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SECTION II-
MEDICATION IIlSI'ORY 
1. WHICH OF THB FOLLOWING MEDICATIONS ARE PRESCRIBED FOR YOU NOW? 
~ PLEASE CHECK ALL THAT APPLY: 
0 Arr (R.etrovir®, zidovudine) 
0 DOI (Videx®, didanosine) 
0 DOC (Hivid®, zalcitabine) 
0 D4T (Zerit®, stavudine) 
0 3TC (Epivir®, lamivudine) 
0 Nevirapine (Viramune®) 
0 Delavirdine (R.escriptor®) 
0 Saquinavir (lnvirase®) 
0 Ritonavir (Norvir®) 
0 Nelfinavir (Vira~pt®) 
0 lndinavir (Crixivan®) 
0 Trimethoprim· or SulfamethQ;tazol~ (Bactrim®, Septra®) 
0 Clarithromycin (Biaxin®) 
0 Dapsone 
0 Fluconazole (Diflucan®) 
0 ltraconazole (Sporanox®) 
0 Rifabutin (Mycobutin®) 
2. How long have you been taking your protease inhibitor medication? 
[Saquinavir (Invirme<!i>), RUonavir (Norrir@), NeQinavir (Vuucept) or IruUnavir (CrixiWJn<!i>)] 
Less than 1 month 6 months to 1 year 
l to 3 months -- 1 to 2 years 
~ ' --
-- 4 to 6 months __ more than 2 years 
3. During the last 3 months, have you ever stopped taking your protease inhil>itor medication because you fdt 
better? 
DYES ONO 
4. During the last 3 months. have you ever stopped talcing your protease inhibitor medication because you fdt 
worse? · 
DYES ONO 
5. During the last 3 months. have you ever forgotten to take your protease inhil>itor medication? 
' . 
DYES 0 NO 
6. During the last 3 months have you at times been careless about taking your protease inhibitor medication? 
DYES 0 NO 
7. During the last 3 months, have you ever taken less of your protease inhibitor medicine than your doctor 
.prescribed because you fdt better? 
DYES D NO 
8. During the last 3 months. have you ever taken less of your protease inlul>itor medicine than your doctor 
prcscnl>cd because you fdt worse? 
DYES D NO 
94 
9. Sinu you began ta.king your protease inhibitor medication, have you ever purposely: 
'YES NO 
a) 
b) 
c) 
taken more of the medicine 0 0 
than your physician prescribed? 
taken less of the medicine 0 0 
than your physician prescribed? 
discontinued or stopped taking 0 0 
your medication? 
/[yes, 
:::> 10.a) How many times have you discontinued your protease inhibitor medication for more 
than 3 days? 
b) What were your reasons for discontinuing your protease inhibitor medication? 
Please check all that apply 
0 My doctor ·recommended it 
0 Too many side effects 
0 I didn't want to be reminded of my illness 
0 Problems with insurance coverage 
0 .I didn't think it was working 
0 Other:_·----------
11. Sometimes it is difficult to take prescribed medicine all the time. During the past week, how many 
times did you miss a dose of your protease inhibitor? 
12. During the past month, about how many times did you miss a dose of your protease 
inhibitor'! ___ _ 
13. During the past three mon~. aooJt how many times did you miss a dose of your protease 
inhibitor? 
----
14. Please check any side effect(s) you are having that you believe are caused by your protease inhibitor 
medicine: 
0 l\all~ 
0 dizziness 
0 vomiting 
0 abdominal pain 
0 diarrhea 
0 other: 
0 shortness of breath 
0 muscle aches 
0 fatigue 
0 tingling in hands/feet 
0 numbness in hands/feet 
95 
0 headaches 
0 anxiety/worry 
0 depression 
0 rash 
0 sensitivity to sun 
·1s. How Jong have you been taking your antiviral medication? • 
[AZT (Rctrol".r®, zUlovudint), DDI (Vida@, didanosint), DDC (Hivid@, raldlabint), 
D4T ~ril®, stavudint), 3TC (Epivir®, lamivudinc), or Nnirapint (V'uomunt)} 
__ .l.o3-lhan 1 month __ 6 months to l year 
1 to 3 months __ 1 to 2 years 
4 to 6 months __ more than 2 years 
16. During the last 3 months have you ever stopped taking your antiviral medication because you fdt better? 
0 YES 0 NO 
17. During the last 3 months, have you ever stopped taking your antiviral medication because you felt worse? 
0 YES D NO 
18. During the last 3 months, have you ever forgotten to take your antiviral medication? 
DYES D NO 
19. During the last 3 montlu have you at times been careless about taking your antiviral medication? 
0 YES 0 NO 
20. During the last 3 months, have you ever taken Jess of your antiviral medicine than your doctor prcscnl>ed 
because you (dt better? 
0 YES D NO 
21. During the last J months, have you ever taken less of your antiviral medicine than your doctor prescnl>ed 
because you fdt worse? 
DYES 0 NO 
22. Since you btgan taking your antiviral medication, have you ever purposely: 
a) 
b) 
c) 
YES NO 
taken more of the medicine 0 0 
than your physician prescribed? 
taken less of the medicine 0 0 
than your physician prescribed? 
discontinued or stopped talcing 0 0 
your medication? 
If yes, 
=:> 23.a) How many times have you discontinued your antiviral medication for more than 3 
days? 
96 
b) What were your reasons for discontinuing your antiviral medic:ition? 
Please check all thar apply 
0 My doCtor recommended it 
0 Too many side effects 
0 I didn't want to be reminded of my illness 
0 Problems with insurance coverage 
0 I didn't think it was working 
0 Other:------------
24. Sometimes it is difficult to take prescribed medicine all the time. During the past week, how mnny 
times did you miss a dose of your antiviral medication? 
25. During the past month, about how many times did you miss a dose of your antiviral 
medication? ___ _ 
· 26. During the past three months, about how many times did you miss a dose of your antiviral 
. medication? · 
TT. Please check any side effecl(s) you arc having that you believe are caused by your antiviral medicine: 
0 nausea 
D dizziness 
0 vomiting 
0 abdominal pain 
0 diarrhea 
0 other: 
0 shortness of breath 0 headaches 
0 muscle aches 0 anxiety/worry 
0 .fatigue 0 depression 
0 tingling in hands/feet 0 rash 
0 numbness in hands/feet 0 sensitivity to sun 
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SECTION III 
ANTIVIRAL MEDICATIONS 
REMINDER: FILL our THIS SECTION IF YOU HA VB BYER TAKEN ANY OF THESE ANTIVIRAL 
MEDICATIONS: AZT (Relrovir®, zidovudine), DDl (Videx®, didanorlne), DDC (Hivid®, z:alcitabin1), 
D4T (Zerit@, stavudlne), 3TC (Epivir®, lamivudine). Neviropine (Vuumune®), or IHlavirdine 
(Rescriptor®). 
::::> 1f you are taking more tf?!!ll O"!:e c.n.tiviral medication NOW, pltase answer these questions 
for the medicine that is most di[fiat.l:t for JOU to take, and fill in the name of that 
medicine hen 
~~~~~~~~~~~~~~~~~~-
::::> 1f you "JuJve discontinued your antiviral medication, pkase answer thest1 questions 
for the medicine that you took most ncaitly, and fill in the name of that 
medicine hen 
~~~~~~~~~~~~~~~~~~-
Taking medications a.S directed (the prescribed amount taken at the right time) is not always c:osy. At 
one time or another most people simply for~ to take a dose of their medication, and sometimes people 
discontinue taking their medications for a while. lbe following is a list of Possible advantages and 
disadvantages of taking antiviral medications as dicectcd. 
l. 
2. 
3. 
4. 
5. 
::::> For each rwmberlll stawnent, please mark one box with an ·x· to rate HOW IMPORTANT that 
statement is to you when you are thinking about whnher to take your antiviral medicalion as 
directed. 
NOT SLIGBTI.Y MODERAn:LY VEXY EXTREMELY 
IM!'OltTAh"T IMlORTAh"T IMl'ORTANT IMl'ORTANT IM?QRTANT 
If I take my antiviral medication 0 0 0 D 0 
as directed, I can avoid possible 
complications of HIV infection. 
When I take my antiviral medication 0 D D D D 
as directed, it makes me feel depressed 
about having RN infection. 
Taking my antiviral medication as directed 0 D 0 D D 
causes too many annoying side effects. 
Taking my antiviral medication as directed 0 0 0 D 0 
will slow down this illness. 
I worry that taking all the doses that are 0 D 0 D 0 
prescribed might not be good for me. 
UniwrU/y of Rluxl~ blonJ. "1996 
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NOT SUGHTLY MODERATELY VERY EXTllD>IEL y 
IMJ'OKTANT IMJ'QRTANT llll?ORTANT lllll'ORTANT IM?'ORTANT 
6. Taking my antiviral medication as directed D 0 0 0 0 
gives me hope. 
7. I worry that the antiviral medication D 0 0 0 0 
. is-doing more harm than good . 
8. Taking my antiviral medication as directed D 0 CT 0 0 
may help me stay well longer. 
9. It may be hard on my system, if I take D 0 D 0 D 
my antiviral medication as directed. 
10. Taking my antiviral medication as directed 0 D D 0 0 
will help me feel better. 
Sometimes people take their medications as di_rccted for a while, and then stop taking them for a while. 
=> ~following 2 qu~tions are about how you are taking your antiYiral mediauion RIGHT NOW. 
11. Do you consistently take your antiviral medication as dirccted7 (Mas directedft means taking your 
medication at the right time and taking the prescribed amount) 
a. Ne., I <io uot, ~d I am not considering taking my antiviral medication as 
directed. 
b. No, I do not, but I am considuing taking my antiviral medication as directed. 
c. No, I do not, but I am planning to start taking my antiviral medication as directed 
within the next month. 
d. Yes, I consistently take my antiviral medication as directed. 
= 12. How long have you been taking your antiviral medication as 
directed? 
a. 0-3 months 
b. 4-6 months 
c. 6-12 months 
d. more than 12 months 
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Now here arr: some situations that might affect whether you take your antiviral medication for HIV 
infection as directed. 
=:> For each situation. please mark one box with an ·x· to raJt HOW TEMPTED you would bt to 
skip your antiviral mMication or tukt a dost which ls difftrtnt from tht one prtScribtd. 
NOT AT SUClrTl.Y MODERAn:LY VERY EXTllEMELY 
ALL TEMJ'TC) TDO'TED TEMl'TED TEMrnD TEMrnD 
13. When you feel good and think you don't ·o D Lf 0 0 
need it. 
14. When you are anxious about side D 0 0 0 0 
effects. 
l~. When you experience minor side effects. 0 0 0 0 D 
16. When your medical condition doesn't D 0 0 0 0 
seem that bad. 
17. When it seems too complex to keep track 0 0 D 0 0 
of all your medications. 
18. When you feel like giving up. 0 0 0 0 0 
19. When you aren't sure if the medicine is 0 0 D 0 0 
really helping you. 
20. When your family or friends don't seem 0 0 0 0 0 
concerned enough about your condition. 
21. When your doctor doesn't seem concerned 0 0 0 0 0 
enough about your condition. 
22.. When your insurance doesn't cover 0 0 D D D 
the cost of your medication. 
23. When you lose confidence in your doctor. 0 0 0 D 0 
24. When you feel you should give your body 0 0 0 0 0 
a rest. 
25. When you worry that the chemicals in the 0 0 0 0 0 
medication might harm or hurt your 
body. 
UV.....Oy of llJooJ. WAM. DJP\>6 
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SECTION IV. 
PROTEASE INHIBITOR MEDICATIONS 
REMINDER: FILL our THIS SECTION IF YOU HA VB BVBR TAKEN ANY OF THESE PROTEA.SB 
INHmITOR MEDICATIONS: Saquirurrir (lnvira.st®), Ritonavir (Norvir®), Ntlfuiavir (Virocept@) or 
Indina11ir (Crixi11an@). 
=> If you an taking more than ont protease inlUbitor medication NOW, please answer these 
questions for tht nwiidne that is most dUficult for you (o taki;, and fill in tht r.i:me of 
thal medicine htrc •• 
=> If you hCll'e disconmwed your protease inhWitor medication, please answer these questions for 
the medicine that you took m'1St recently, and fill in the namt of thal medicine here 
Taking medications as directed (the prescribed amount taken at the right time) is not always easy. At 
one time or another most people simply forget to take a dose of their medication, and sometimes people 
discontinue taking their medications for a while. 1'be following is a list of possible advantages and 
disadvantages of taking protease inhibitor medications as directed. 
=> For each numbered statement, p~ maric one box with an ·x· to rote HOW IMPORTANT that 
.staJcnent i.s to )'OM when you are thinking about whtthtr to take your protease inhibitor 
medication as dincted. 
NOT SUCBTLY MODERATELY VERY EXTREMELY 
D\a'OltT ANT IM!'OKT ANT IMPORTANT IMl'ORTANT IMl'ORTANT 
1. If I take my protease inhibitor medication D D D D D 
as directed, I can avoid possible 
complications of HIV infection. 
2. When I take my protease inhibitor D D 0 0 0 
medication as directed. it makes me feel 
depressed about having HIV infection. 
3. Taking my protease inhibitor medication D D D 0 0 
as directed causes too many annoying 
side effects. 
4. Taking my protease inhibitor medication D 0 D D D 
as directed will slow down this illness. 
5. I worry that taking all the doses that are D D D 0 D 
prescribed might not be good for me. 
6. Taking my protease inhibitor medication D 0 D 0 0 
as directed gives me hope. 
Unlwnil'J of 1Vt.otU lsltutJ, D/996 
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NOT SUCllTLY. MOD£RAT£LY V'DtY EXTltEMELY 
IMroRTANT l!llroRTANT IM?'ORT AN!' IMroRTANJ' IMroRTANT 
' · 
I worry that the protease inhibitor 0 0 D D ·o 
medication is doing more harm 
than good. 
8. Talcing my protease inhibitor medication 0 0 0 D 0 
as directed may help me stay well longer. 
9. It may be hard on my system, if I take my D 0 o· D 0 
protease inhibitor medication as directed. 
10. Talcing my protease inhibitor medication 0 0 D D 0 
as directed will help me feel better. 
Soiµetimes people take their medications as directed for a while, and then stop taking them for a while. 
~ The follcwing 2 qru.stions all about how you all taking your prouase inhibitor medication 
RIGHT NOW. 
11. Do you consistently take your protease inhibitor medication as dircctcd7 c·as directed~ means talcing 
your medication at the right time and talcing the prescribed amount) 
__ a. No, I do not, and I am not considering talcing my protease inhibitor medication as 
directed. 
b. No, I do not, but I am considering taking my protease inhibitor medication as 
directed. 
c. No, I do not, but I am planning to start talcing my protease inhibitor medication as 
directed within the next month. 
d. Yes, I consistently ta1ce my protease inhibitor medication as directed. 
=;> 12. How long have you been taking your protease inhibitor medication as 
directed7 
a. 0-3 months 
b. 4-6 months 
c. &-12 months 
d. more than 12 months 
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Now here arc some situations that might affcc:t whether you Ukc your protease inhibitor medication 
for HIV infection as directed. 
:::::> For tach situation, pltast mark ont bo:c with an -x· to rott HOW TEMPTED you would bt to 
skip your prottast inhibitor mtdication or take a dose which ls difftlllllfrom the one 
prtscribtd. 
NOT AT SUGBTLY MODDlATELY VERY EXI'IU:MELY 
AU~ TEMJ"n;J> Tu.lrn:D TEMrrED TEMPTED 
~. 
13. When you feel good and think you don't D D D ·D 0 
need it. 
14. When you arc anxious about side effects. D D 0 D 0 
15. When you experience minor side effects. D D 0 0 D 
16. When your medical condition doesn't D D 0 D D 
seem that bad. 
17. When it seems too complex to keep tra<:~ D D 0 0 D 
of all your medications. 
18. When you feel like giving up. D D 0 D D 
19. When you aren't sure if the mcdici.Qe is D D 0 0 D 
; really helping you. 
20. When your family or friends don't seem D D 0 0 0 
concerned enough about your condition. 
21. When your doctor doesn't seem D D 0 D D 
concerned enough about your condition. 
22. When your insurance doesn't cover 0 0 0 0 0 
the cost of your medication. 
23. When you lose confidence in your doctor. D D 0 0 D 
24. When you feel you should give your body 0 D D 0 0 
a rest. 
25. When you worry that the chemicals in the D D 0 0 D 
medication might hann or hurt your 
body. 
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For information on !he MMcdication for The Needy-Assistance Program• at The Univcrsiry or Rhode Island, 
call 1-800-215-9001. 
This completes this survey. Thank you for your assistance with th1s project & for sharing your 
thoughts on HIV related medications. 
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libname research 'd:\research'; 
data research.new; 
set research.hivshrt; 
*new variable for age called agegrp coded as 1,2,3 and 4; 
if 20 le qi1 le 25 then agegrp=1; 
else if 26 le qi1 le 35then agegrp=2; 
else if 36 le qi1 le 45 then agegrp=3; 
else if 46 le qi1 le 55 then agegrp=4; 
*new variable for education called edu coded as 1 2 3 and 4; 
if qi5<12 then edu=1; 
else if qi5=12 then edu=2; 
else if 13 le qi5 le 15 then edu=3; 
else if qi5 ge 15 then edu=4; 
*new variable for employment called emp coded as 1 2 
if qi6=1 or qi6=2 then emp=2; 
else if qi6=3 then emp=1; 
*recoding for drugnam1 drunam2 and drugnam3 1=pi 2=ar and 3=ai; 
if drugnam1='saqinavir' or drugnam1='invirase' or drugnam1='ritonavir 
or drugnam1='norvir' or drugnam1='crixivan' or drugnam1='nelfinavir' 
then drugnam1=1; 
else if drugnam1=' ' then drugnam1=' .'; 
else if drugnam1= 'AZT' or drugnam1= 'retrovir' or drugnam1= 'zidovud 
or drugnam1='videx' or drugnam1= 'didanosine'or drugnam1='DDC' or dru 
drugnam1= 'zalcitabine' or drugnam1= 'D4T' or drugnam1= 'zerit' or dr 
drugnam1= '3TC' or drugnam1='epivir' or drugnam1='lamivudine' or drug 
or drugnam1='viramune' or drugnam1='delavirdine' or drugnam1= 'rescri 
else drugnam1=3; 
if drugnam2='saqinavir' or drugnam2='invirase' or drugnam2='ritonavir 
or drugnam2='norvir' or drugnam2='crixivan' or drugnam2='nelfinavir' 
then drugnam2=1; 
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else if drugnam2=' ' then drugnam2=' .'; 
else if drugnam2= 'AZT' or drugnam2= 'retrovir' or drugnam2= 'zidovud 
or drugnam2='videx' or drugnam2= 'didanosine'or drugnam2='DDC' or dru 
drugnam2= 'zalcitabine' or drugnam2= 'D4T' or drugnam2= 'zerit' or dr 
drugnam2= '3TC' or drugnam2='epivir' or drugnam2='lamivudine' or drug 
or drugnam2='viramune' or drugnam2='delavirdine' or drugnam2= 'rescri 
else drugnam2=3; 
if drugna~3='saqinavir' or drugnam3='invirase' or drugnam3='ritonavir 
or drugnam3='norvir' or drugnam3='crixivan' or drugnam3='nelfinavir' 
then drugnam3=1; 
else if drugnam3=' ' then drugnam3='. '; 
else if drugnam3= 'AZT' or drugnam3= 'retrovir' or drugnam3= 'zidovud 
or drugnam3='videx' or drugnam3= 'didanosine'or drugnam3='DDC' or dru 
drugnam3= 'zalcitabine' or drugnam3= 'D4T' or drugnam3= •zerit' or dr 
drugnam3= '3TC' or drugnam3='epivir' or drugnam3='lamivudine' or drug 
or drugnam3='viramune' or drugnam3='delavirdine' or drugnam3= 'rescri 
else drugnam3=3; 
*recoding the variables included in the mas scale as O and 1; 
if qiiav16=1 then qiiav16=0; 
else if qiiav16=2 then qiiav16=1; 
else qiiav16='. •; 
if qiiav17=1 then qiiav17=0; 
else if qiiav17=2 then qiiav17=1; 
else qiiav17='. •; 
if qiiav18=1 ~hen qiiav1B=O; 
else if qiiav18=2 then qiiav18=1; 
else qiiav18='. •; 
if qiiav19=1 then qiiav19=0; 
else if qiiav19=2 then qiiav19=1; 
else qiiav19='. •; 
if qiiav20=1 then qiiav20=0; 
else if qiiav20=2 then qiiav20=1; 
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else qiiav20='. '; 
if qiiav21=1 then qiiav21=0; 
else if qiiav21=2 then qiiav21=1; 
else qiiav21='.'; 
if qiipi3=1 then qiipi3=0; 
else if qiipi3=2 then qiipi3=1; 
else qiipi3='.'; 
if _qiipi4=1 then qiipi4=0; 
else if qiipi4=2 then qiipi4=1; 
else qiipi4='.'; 
if qiipi5=1 then qiipi5=0; 
else if qiipi5=2 then qiipi5=1; 
else qiipi5='. •; 
if qiipi6=1 then qiipi6=0; 
else if qiipi6=2 then qiipi6=1; 
else qiipi6='.'; 
if qiipi7=1 then qiipi7=0; 
else if qiipi7=2 then qiipi7=1; 
else qiipi7='. '; 
if qiipi8=1 then qiipiS=O; 
else if qiipi8=2 then qiipi8=1; 
else qiipi8='.'; 
MAS AV= qiiav16+qiiav17+qiiav18+qiiav19+qiiav20+qiiav21; 
MAS PI= qiipi3+qiipi4+qiipi5+qiipi6+qiipi7+qiipi8; 
TEMP13AV= qiii23+qiii24+qiii28+qiii34+qiii36+qiii37+qiii40+ 
qiii44+qiii47+qiii48+qiii49+qiii51+qiii52; 
TEMP12AV= qiii23+qiii24+qiii28+qiii34+qiii36+qiii40+ 
qiii44+qiii47+qiii48+qiii49+qiii51+qiii52; 
TEMP13PI=qv23+qv24+qv28+qv34+qv36+qv37+qv40+qv44+qv47+qv48+qv49+qv51+ 
TEMP12PI= qv23+qv24+qv28+qv34+qv36+qv40+qv44+qv47+qv48+qv49+qv51+qv52 
*avm1 avm2 avm3 are three sub categories for mas av and pim1 pim2 pim 
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if mas_av=O then avm1=0; 
else if 1 le mas av le 6 then avm1=1; 
else avm1='. •; 
if mas av=O or mas_av=1 then avm2=0; 
else if 2 le mas av le 6 then avm2=1; 
else avm2=' . • ; 
if mas_av=O or mas_av=1 or mas av=2 ~hen avm3=0; 
else if 3 le mas av le 6 then avm3=1; 
else avm3= • . • ; 
if mas_pi=O then pim1=0; 
else if 1 le mas_pi le 6 then pim1=1; 
else pim1='. '; 
if mas_pi=O or mas_pi=1 then pim2=0; 
else if 2 le mas_pi le 6 then pim2=1; 
else pim2= • . • ; 
if mas_pi=O or mas_pi=1 or mas_pi=2 then pim3=0; 
else if 3 le mas_pi le 6 then pim3=1; 
else pim3='.'; 
if temp12av=12 then av12t1=0; 
else if 13 le temp12av le 38 then av12t1=1; 
else av12t1='.'; 
if temp12av=12 or temp12av=13 then av12t2=0; 
else if 14 le temp12av le 38 then av12t2=1; 
else av12t2='. •; 
if temp12av=12 or temp12av=13 or temp12av=14 then av12t3=0; 
else if 15 le temp12av le 38 then av12t3=1; 
else av12t3=' .'; 
if temp12av=12 or temp12av=13 or temp12av=14 or temp12av=15 then av12 
else if 16 le temp12av le 38 then av12t4=1; 
else av12t4=' .'; 
if temp13av=13 then av13t1=0; 
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else if 14 le temp13av le 42 then av13t1=1; 
else av13t1='.'; 
if temp13av=13 or temp13av=14 then av13t2=0; 
else if 15 le temp13av le 42 then av13t2=1; 
else av13t2='.'; 
if temp13av=13 or temp13av=14 or temp13av=15 then av13t3=0; 
else if 16 le temp13av le 42 then av13t3=1; 
else av13t3=' . ' ; 
if temp13av=13 or temp13av=14 or temp13av=15 or temp13av=16 then av13 
else if 17 le temp13av le 42 then av13t4=1; 
else av13t4=' . ' ; 
if temp12pi=12 then pi12t1=0; 
else if 13 le temp12pi le 60 then pi12t1=1; 
else pi12t1='. • ; 
if temp13pi=13 then pi13t1=0; 
else if 14 le temp13pi le 65 then pi13t1=1; 
else pi13t1=' . ' ; 
if 80 le dosepct1 le 100 then mems1=0; 
else if dosepct1=. then mems1=.; 
else mems1=1; 
if 90 le dosepct1 le 100 then mems2=0; 
else if dosepct1=. then mems2=.; 
else mems2=1; 
* new variable for # doses missed; 
OM= {90-qiipi12}/90*100; 
TM= {270-qiipi13}/270*100; 
if 80 le om le 100 then om1=0; 
else if om=. then om1=.; 
else om1=1; 
if 90 le om le 100 then om2=0; 
else if om=. then om2=.; 
else om2=1; 
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if 80 le tm le 100 then tm1=0; 
else if tm=. then tm1=.; 
else tm1=1; 
if 90 le tm le 100 then tm2=0; 
else if tm=. then tm2=.; 
else tm2=1; 
run; 
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